US20090215674A1 - Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent - Google Patents
Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent Download PDFInfo
- Publication number
- US20090215674A1 US20090215674A1 US12/332,880 US33288008A US2009215674A1 US 20090215674 A1 US20090215674 A1 US 20090215674A1 US 33288008 A US33288008 A US 33288008A US 2009215674 A1 US2009215674 A1 US 2009215674A1
- Authority
- US
- United States
- Prior art keywords
- hydrogen
- polyene macrolide
- antibacterial agent
- group
- glycopeptide antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title claims abstract description 111
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 111
- 108010015899 Glycopeptides Proteins 0.000 title claims abstract description 110
- 102000002068 Glycopeptides Human genes 0.000 title claims abstract description 110
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 109
- 239000003429 antifungal agent Substances 0.000 title claims abstract description 100
- 239000003120 macrolide antibiotic agent Substances 0.000 title claims abstract description 88
- 150000004291 polyenes Chemical class 0.000 title claims abstract description 88
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 42
- 125000001424 substituent group Chemical group 0.000 claims abstract description 36
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 19
- 208000031888 Mycoses Diseases 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- -1 -(phenyl) Chemical group 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 27
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 23
- 229960003942 amphotericin b Drugs 0.000 claims description 20
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 229960000988 nystatin Drugs 0.000 claims description 10
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 10
- 108010053950 Teicoplanin Proteins 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- DPAGRPSAFDXQDN-UHFFFAOYSA-N 5-methoxy-8,8-dimethyl-2-phenyl-4H,8H-pyrano[2,3-h]chromen-4-one Chemical compound C=1C(=O)C=2C(OC)=CC=3OC(C)(C)C=CC=3C=2OC=1C1=CC=CC=C1 DPAGRPSAFDXQDN-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 8
- 229960001608 teicoplanin Drugs 0.000 claims description 8
- 108700009376 dalbavancin Proteins 0.000 claims description 6
- 229960002488 dalbavancin Drugs 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 108010089019 telavancin Proteins 0.000 claims description 6
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims description 6
- 229960005240 telavancin Drugs 0.000 claims description 6
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims description 6
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 claims description 5
- NCXMLFZGDNKEPB-UHFFFAOYSA-N Pimaricin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCC(C)OC(=O)C=CC2OC2CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 NCXMLFZGDNKEPB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004348 candicidin Drugs 0.000 claims description 5
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 5
- 229960003255 natamycin Drugs 0.000 claims description 5
- 108010006945 oritavancin Proteins 0.000 claims description 5
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims description 5
- 229960001607 oritavancin Drugs 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- GXLOOVOKGBOVIH-YPBFURFVSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,29r,32r,33r,35s,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,29,32,33,35,37-heptahydroxy-18,20,21-trimethyl-23,27-dioxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)CC(=O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 GXLOOVOKGBOVIH-YPBFURFVSA-N 0.000 claims description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 4
- CYGXFHUZSVKTBA-MOAKSMKPSA-N Candidin Natural products C[C@H]1OC(=O)C[C@@H](O)C[C@@H](O)CC(=O)CC[C@@H](O)[C@H](O)CC(=O)C[C@@H](O)[C@H]([C@H](O)C[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C=CC=CC=CC=CC=CC=CC=C[C@@H](C)[C@H](O)[C@@H]1C)C(=O)O CYGXFHUZSVKTBA-MOAKSMKPSA-N 0.000 claims description 4
- GXLOOVOKGBOVIH-UHFFFAOYSA-N Mycoheptin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CC=CC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(=O)CC(O)CCC(O)C(O)CC(O)(CC(O)C2C(O)=O)OC2C1 GXLOOVOKGBOVIH-UHFFFAOYSA-N 0.000 claims description 4
- DXENDDMPDZMHSQ-UHFFFAOYSA-N Qingdainone Natural products C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1C2=C1C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229930188428 trichomycin Natural products 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 42
- 239000000203 mixture Substances 0.000 abstract description 31
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 238000003556 assay Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 229940126062 Compound A Drugs 0.000 description 15
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000000843 anti-fungal effect Effects 0.000 description 12
- 239000002054 inoculum Substances 0.000 description 12
- 230000002195 synergetic effect Effects 0.000 description 12
- 150000001720 carbohydrates Chemical group 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229960001031 glucose Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 6
- 241000222173 Candida parapsilosis Species 0.000 description 6
- 241000221204 Cryptococcus neoformans Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 108010059993 Vancomycin Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000008121 dextrose Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000012449 sabouraud dextrose agar Substances 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 6
- 229960003165 vancomycin Drugs 0.000 description 6
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 241000222178 Candida tropicalis Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 241000235645 Pichia kudriavzevii Species 0.000 description 5
- 0 [1*]N[C@@]1(C)C[C@H](O[C@H]2[C@H](OC3=C4C=C5C=C3OC3=C(C)C=C(C=C3)[C@@H](O[6*])[C@]3([H])NC(=O)[C@]([H])(NC(=O)[C@]5([H])NC(=O)[C@H](CC(N)=O)NC(=O)[C@]([H])(NC(=O)[C@@H](CC(C)C)N([4*])[5*])[C@H](O)C5=CC=C(O4)C(C)=C5)C4=CC(=C(O)C=C4)C4=C(O)C([7*])=C(O)C=C4[C@@H](C(=O)O)NC3=O)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@]1([2*])[3*] Chemical compound [1*]N[C@@]1(C)C[C@H](O[C@H]2[C@H](OC3=C4C=C5C=C3OC3=C(C)C=C(C=C3)[C@@H](O[6*])[C@]3([H])NC(=O)[C@]([H])(NC(=O)[C@]5([H])NC(=O)[C@H](CC(N)=O)NC(=O)[C@]([H])(NC(=O)[C@@H](CC(C)C)N([4*])[5*])[C@H](O)C5=CC=C(O4)C(C)=C5)C4=CC(=C(O)C=C4)C4=C(O)C([7*])=C(O)C=C4[C@@H](C(=O)O)NC3=O)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@]1([2*])[3*] 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 239000001965 potato dextrose agar Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- GPYLWKMYVPRKSH-UHFFFAOYSA-N CC(C)CNCP(=O)(O)O Chemical compound CC(C)CNCP(=O)(O)O GPYLWKMYVPRKSH-UHFFFAOYSA-N 0.000 description 4
- YWQTXHIJYXMRPW-UTINFBMNSA-N CC(C)[C@@H]1C[C@@](C)(N)[C@H](O)[C@@H](C)O1 Chemical compound CC(C)[C@@H]1C[C@@](C)(N)[C@H](O)[C@@H](C)O1 YWQTXHIJYXMRPW-UTINFBMNSA-N 0.000 description 4
- 201000007336 Cryptococcosis Diseases 0.000 description 4
- 241000233732 Fusarium verticillioides Species 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 150000007931 macrolactones Chemical group 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000228197 Aspergillus flavus Species 0.000 description 3
- 241001225321 Aspergillus fumigatus Species 0.000 description 3
- BOWKEZIHDUGWRW-UHFFFAOYSA-N CCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1 Chemical compound CCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1 BOWKEZIHDUGWRW-UHFFFAOYSA-N 0.000 description 3
- 244000197813 Camelina sativa Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000306281 Mucor ambiguus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 241000223598 Scedosporium boydii Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- OIJZDPGKNVKVBL-UHFFFAOYSA-N Vancosamine Natural products CC1OC(O)CC(C)(N)C1O OIJZDPGKNVKVBL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002815 broth microdilution Methods 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007430 reference method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WPJRFCZKZXBUNI-JKUQZMGJSA-N (3r,4r,5s)-3-amino-4,5-dihydroxyhexanal Chemical compound C[C@H](O)[C@H](O)[C@H](N)CC=O WPJRFCZKZXBUNI-JKUQZMGJSA-N 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical compound CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- ZECQVPSAXSIXIC-UHFFFAOYSA-N Actinosamine Natural products COC1C(C)OC(O)CC1N ZECQVPSAXSIXIC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- BBMKQGIZNKEDOX-UHFFFAOYSA-N D-Acosamin Natural products CC1OC(O)CC(N)C1O BBMKQGIZNKEDOX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 108010081391 Ristocetin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WPJRFCZKZXBUNI-KVQBGUIXSA-N acosamine Chemical compound C[C@H](O)[C@@H](O)[C@H](N)CC=O WPJRFCZKZXBUNI-KVQBGUIXSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229940055022 candida parapsilosis Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- WPJRFCZKZXBUNI-HCWXCVPCSA-N daunosamine Chemical compound C[C@H](O)[C@@H](O)[C@@H](N)CC=O WPJRFCZKZXBUNI-HCWXCVPCSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- YMWQIYMUNZBOOV-DOZYEWNNSA-N teichomycin a2-1 Chemical compound CCCCC\C=C/CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@H](C3=CC(O)=CC(O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(O)=O)=O)Cl)=C(OC=2C(=CC(C[C@H](C(N4)=O)NC(=O)[C@@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 YMWQIYMUNZBOOV-DOZYEWNNSA-N 0.000 description 2
- 150000005672 tetraenes Chemical class 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960004740 voriconazole Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- BJNLLBUOHPVGFT-CAYRISATSA-N (1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid Chemical compound CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(OC4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl BJNLLBUOHPVGFT-CAYRISATSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 description 1
- IJSNCWAAHIVVGJ-XVMARJQXSA-N (3s,4s,5s)-3-amino-4,5-dihydroxy-3-methylhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@](C)(N)CC=O IJSNCWAAHIVVGJ-XVMARJQXSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GHQHKPMLGYLYEI-UHFFFAOYSA-N 1H-pyrrole Chemical compound C=1C=CNC=1.C=1C=CNC=1.C=1C=CNC=1 GHQHKPMLGYLYEI-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UXCMNUUPBMYDLJ-UHFFFAOYSA-N 4-(4-chlorophenyl)benzaldehyde Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C=O)C=C1 UXCMNUUPBMYDLJ-UHFFFAOYSA-N 0.000 description 1
- HDNVYHWHCVTDIV-UHFFFAOYSA-N 4-[(2-amino-3-hydroxy-2-methylpropanoyl)amino]-n-[1-[5-[5-(dimethylamino)-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]-2-oxopyrimidin-4-yl]benzamide Chemical compound CC1OC(N2C(N=C(NC(=O)C=3C=CC(NC(=O)C(C)(N)CO)=CC=3)C=C2)=O)CCC1OC1OC(C)C(N(C)C)C(O)C1O HDNVYHWHCVTDIV-UHFFFAOYSA-N 0.000 description 1
- BURNGCVAUVZERJ-BNSVOVDNSA-N 64n95c5mao Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(N)C2)OC2=CC=C(C=C2)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 BURNGCVAUVZERJ-BNSVOVDNSA-N 0.000 description 1
- 108010042588 A 41030 Proteins 0.000 description 1
- 108010061385 AB 65 Proteins 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000293034 Apophysomyces elegans Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 239000004184 Avoparcin Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000754798 Calophyllum brasiliense Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222157 Candida viswanathii Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 241000293020 Cokeromyces recurvatus Species 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000550645 Danaea media Species 0.000 description 1
- 229930185464 Dermostatin Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014684 Endocarditis staphylococcal Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930183931 Filipin Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000144128 Lichtheimia corymbifera Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000293032 Mucor ramosissimus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 108700005483 N-demethylvancomycin Proteins 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000222051 Papiliotrema laurentii Species 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 241000235056 Pichia norvegensis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000593344 Rhizopus microsporus Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 241000872726 Rhizopus pusillus Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241000293025 Saksenaea vasiformis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 206010056430 Staphylococcal sepsis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000736855 Syncephalastrum racemosum Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 241000191353 [Candida] haemulonis Species 0.000 description 1
- ZHRODENVJFUAFN-PNKCYDOPSA-N aad 216 Chemical compound CCC(=O)N[C@H]1C(O)O[C@H](C(O)=O)[C@@H](O)[C@@H]1O.N1C(=O)C(NC(C(NC)C=2C=C(O3)C(O)=CC=2)=O)C(O)C(C=C2Cl)=CC=C2OC(C=2O)=CC4=CC=2OC(C(=C2)Cl)=C(Cl)C=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C5C=2)C(O)=O)=O)NC(=O)C5NC(=O)C4NC(=O)C1C1=CC3=CC(O)=C1Cl ZHRODENVJFUAFN-PNKCYDOPSA-N 0.000 description 1
- FGDOJVYPUSOORV-BKPBQXSSSA-N ac1l3yzg Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)C(C)CC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 FGDOJVYPUSOORV-BKPBQXSSSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- BDNDRNLSLGGULA-UHFFFAOYSA-N actaplanin Chemical compound C=1C2=CC=C(O)C=1C1=C(OC3C(C(O)C(O)C(CO)O3)O)C=C(O)C=C1C(C(=O)OC)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(C=3C=C(C(=C(O)C=3)C)OC=3C(O)=CC=C(C=3)C(N)C(=O)N3)NC(=O)C3CC(C=C3)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)O)=CC2=CC=3OC(C(=C2)Cl)=CC=C2C1OC1CC(N)C(O)C(C)O1 BDNDRNLSLGGULA-UHFFFAOYSA-N 0.000 description 1
- 108010020588 actaplanin Proteins 0.000 description 1
- 229950002379 actaplanin Drugs 0.000 description 1
- FHIABUHDBXFQIT-JSNQUVIDSA-N actinoidin Chemical compound O1[C@@H](C)[C@H](OC)[C@@H](N)C[C@@H]1OC(C1C(NC(C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)C(NC(=O)C2NC(=O)C(CC=3C=CC=CC=3)NC(=O)C(NC(=O)C(N)C=3C=CC(O)=CC=3)C(O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](N)C3)C4=CC2=C1 FHIABUHDBXFQIT-JSNQUVIDSA-N 0.000 description 1
- 108700031667 actinoidins Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940098178 ambisome Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- HRGFAEUWEMDRRZ-QLRHZSCISA-N antibiotic a 47934 Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=C(Cl)C=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(OS(O)(=O)=O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 HRGFAEUWEMDRRZ-QLRHZSCISA-N 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229950001376 ardacin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- JWFVWARSGMYXRN-HTQQBIQNSA-N avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 description 1
- 108010053278 avoparcin Proteins 0.000 description 1
- 229950001335 avoparcin Drugs 0.000 description 1
- 235000019377 avoparcin Nutrition 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- WKNFBFHAYANQHF-UHFFFAOYSA-N bahlmycin Natural products C=1C2=CC=C(O)C=1C1=C(O)C=C(O)C=C1C(C(O)=O)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)O)=CC2=CC=3OC(C(=C2)Cl)=CC=C2C1OC1CC(C)(N)C(=O)C(C)O1 WKNFBFHAYANQHF-UHFFFAOYSA-N 0.000 description 1
- WKNFBFHAYANQHF-QITLWLKTSA-N balhimycin Chemical compound O([C@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)OC2=CC=C(C=C2Cl)[C@H](O)[C@@H](C(N[C@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@@H]1C[C@@](C)(N)C(=O)[C@H](C)O1 WKNFBFHAYANQHF-QITLWLKTSA-N 0.000 description 1
- 108700008956 balhimycin Proteins 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical class O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- SJSZMXQSCZCGFO-UHFFFAOYSA-N decaplanin Chemical compound C=1C2=CC=C(O)C=1C1=C(O)C=C(O)C=C1C(C(O)=O)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(C)O4)O)=CC2=CC=3OC(C=C2)=CC=C2C1OC1CC(C)(N)C(O)C(C)O1 SJSZMXQSCZCGFO-UHFFFAOYSA-N 0.000 description 1
- 108010040131 decaplanin Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940063123 diflucan Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- UECIPBUIMXSXEI-BNSVOVDNSA-N eremomycin Chemical compound O([C@@H]1C2=CC=C(C=C2)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(N)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 UECIPBUIMXSXEI-BNSVOVDNSA-N 0.000 description 1
- 108010013356 eremomycin Proteins 0.000 description 1
- UECIPBUIMXSXEI-UHFFFAOYSA-N eremomycin Natural products C=1C2=CC=C(O)C=1C1=C(O)C=C(O)C=C1C(C(O)=O)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)OC4OC(C)C(O)C(C)(N)C4)=CC2=CC=3OC(C=C2)=CC=C2C1OC1CC(C)(N)C(O)C(C)O1 UECIPBUIMXSXEI-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- IMQSIXYSKPIGPD-NKYUYKLDSA-N filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 1
- 229950000152 filipin Drugs 0.000 description 1
- IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- WGLLKNKPWOAHKS-UHFFFAOYSA-N hepta-1,2-dien-1-one Chemical class CCCCC=C=C=O WGLLKNKPWOAHKS-UHFFFAOYSA-N 0.000 description 1
- RYPKRALMXUUNKS-UHFFFAOYSA-N hex-2-ene Chemical class CCCC=CC RYPKRALMXUUNKS-UHFFFAOYSA-N 0.000 description 1
- GJLMVFYLBCBFHA-UHFFFAOYSA-N hexa-1,2-dien-1-one Chemical class CCCC=C=C=O GJLMVFYLBCBFHA-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DTSSDPFTHGBSDX-KVTDHHQDSA-N mycosamine Chemical compound C[C@@H](O)[C@@H](O)[C@H](N)[C@H](O)C=O DTSSDPFTHGBSDX-KVTDHHQDSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940080553 normosol-m Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NVJUPMZQNWDHTL-MJODAWFJSA-N partricin Chemical compound O1C(=O)CC(O)CC(=O)CC(O)CC(O)CC(O)CC(O)CC(O2)(O)CC(O)C(C(O)=O)C2CC(O[C@@H]2[C@@H]([C@H](N)[C@@H](O)[C@H](C)O2)O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C(C)C1C(C)CCC(O)CC(=O)C1=CC=C(N)C=C1 NVJUPMZQNWDHTL-MJODAWFJSA-N 0.000 description 1
- 229950007355 partricin Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- UEHGPSGGFKLPTD-KVTDHHQDSA-N perosamine Chemical compound C[C@@H](O)[C@@H](N)[C@H](O)[C@H](O)C=O UEHGPSGGFKLPTD-KVTDHHQDSA-N 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950004257 ristocetin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940049565 targocid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BJNLLBUOHPVGFT-QRZIFLFXSA-N teichomycin Chemical compound CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@H](C3=CC(O)=CC(O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(O)=O)=O)Cl)=C(OC=2C(=CC(C[C@H](C(N4)=O)NC(=O)[C@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 BJNLLBUOHPVGFT-QRZIFLFXSA-N 0.000 description 1
- GHOXVFYORXUCPY-VPMXZCLFSA-N teichomycin a2-2 Chemical compound CC(C)CCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@H](C3=CC(O)=CC(O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(O)=O)=O)Cl)=C(OC=2C(=CC(C[C@H](C(N4)=O)NC(=O)[C@@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 GHOXVFYORXUCPY-VPMXZCLFSA-N 0.000 description 1
- KSPOYQQCANXEDC-CKUVJKMYSA-N teicoplanin a2-4 Chemical compound CCC(C)CCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@H](C3=CC(O)=CC(O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(O)=O)=O)Cl)=C(OC=2C(=CC(C[C@H](C(N4)=O)NC(=O)[C@@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 KSPOYQQCANXEDC-CKUVJKMYSA-N 0.000 description 1
- FHBQKTSCJKPYIO-OXIGXJDJSA-N teicoplanin a2-5 Chemical compound CC(C)CCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@H](C3=CC(O)=CC(O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(O)=O)=O)Cl)=C(OC=2C(=CC(C[C@H](C(N4)=O)NC(=O)[C@@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 FHBQKTSCJKPYIO-OXIGXJDJSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940010175 vfend Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent. More specifically, this invention relates to methods of using a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent to treat fungal infections; and to compositions, kits and systems comprising a polyene macrolide antifungal agent and a glycopeptide antibacterial agent.
- Polyene macrolide antifungal agents such as amphotericin B and nystatin, are well known in the art for the treatment of fungal Infections.
- polyene macrolide antifungal agents when administered parenterally, have a number of serious side effects including nephrotoxicity. These side effects limit the amount of the polyene macrolide antifungal agent that can be administered safely to a patient and thus, such side effects limit the effectiveness of these antifungal agents.
- the present invention provides a novel method of administering a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent.
- a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms is administered in combination with a polyene macrolide antifungal agent, the efficacy of the polyene macrolide antifungal agent is substantially increased. Accordingly, when used in combination with such a glycopeptide antibacterial agent, the amount of polyene macrolide antifungal agent needed to treat a fungal infection is reduced thereby resulting in fewer side effects.
- this invention provides a method for administering a polyene macrolide antifungal agent to a subject, the method comprising administering to the subject a polyene macrolide antifungal agent and a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- this invention provides a method for treating a fungal infection in a subject, the method comprising administering to the subject an antifungal amount of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- this Invention provides a method for increasing the efficacy of a polyene macrolide antifungal agent, the method comprising administering the polyene macrolide antifungal agent to a subject in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- this invention provides a pharmaceutical composition comprising:
- this invention provides a kit comprising:
- glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- the kit further comprises instructions for administering the antifungal and antibacterial agents to a subject in need of treatment.
- this invention provides a system for treating a fungal infection in a subject, the system comprising:
- glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- This invention is also directed to the use of:
- glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms
- this invention is directed to the use of a polyene macrolide antifungal agent in the manufacture of a medicament for co-administration with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms for the treatment of a fungal infection.
- this invention is directed to the use of a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms In the manufacture of a medicament for co-administration with a polyene macrolide antifungal agent for the treatment of a fungal infection.
- this invention provides a combination comprising:
- glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- the present invention provides a novel method of administering a polyene macrolide antifungal agent to a subject in need of treatment.
- a feature of the present invention is that the polyene macrolide antifungal agent is administered to the subject in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- the antifungal and antibacterial agents may be administered sequentially or simultaneously; and may be in the same or separate formulations.
- alkyl means a monovalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkyl groups typically contain from 1 to 15 carbon atoms. Representative alkyl groups include, by way of example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
- C 8-12 alkyl means an alkyl group having from 8 to 12 carbon atoms.
- alkylene means a divalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkylene groups typically contain from 1 to 10 carbon atoms. Representative alkylene groups include, by way of example, methylene, ethane-1,2-diyl (“ethylene”), propane-1,2-diyl, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl and the like.
- ethylene ethane-1,2-diyl
- propane-1,2-diyl propane-1,3-diyl
- butane-1,4-diyl pentane-1,5-diyl and the like.
- alkoxy means a monovalent group of the formula (alkyl)-O—, where alkyl is as defined herein.
- Representative alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy and the like.
- alkenyl means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon double bonds. Unless otherwise defined, such alkenyl groups typically contain from 2 to 15 carbon atoms. Representative alkenyl groups include, by way of example, ethenyl, n-propenyl, isopropenyl, n-but-2-enyl, n-hex-3-enyl and the like.
- alkynyl means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon triple bonds. Unless otherwise defined, such alkynyl groups typically contain from 2 to 15 carbon atoms. Representative alkynyl groups include, by way of example, ethynyl, n-propynyl, n-but-2-ynyl, n-hex-3-ynyl and the like.
- halo means fluoro, chloro, bromo and iodo.
- saccharide group means an oxidized, reduced or substituted saccharide monoradical covalently attached to the glycopeptide or other compound via any atom of the saccharide moiety, e.g., via the aglycone carbon atom.
- saccharide group includes amino-containing saccharide groups.
- Representative saccharide include, by way of illustration, hexoses such as D-glucose, D-mannose, D-xylose, Dgalactose, vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, D-glucamine, N-methyl-D-glucamine, D-glucuronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, sialyic acid, iduronic acid, L-fucose, and the like; pentoses such as D-ribose or D-arabinose; ketoses such as D-ribulose or D-fructose; disaccharides such as 2-O-( ⁇ -L-vancosaminyl) ⁇ -D-glucopyranose, 2-O
- amino-containing saccharide group means a saccharide group having an amino substituent.
- Representative amino-containing saccharides include L-vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, N-methyl-D-glucamine and the like.
- a “substituent comprising at least 8 carbon atoms” means any substituent having at least 8 carbon atoms which substituent may also contain other atoms such as oxygen, nitrogen, sulfur or halo; or combinations thereof.
- a glycopeptide antibacterial agent such a substituent is attached to either (1) the amino acids (AA 1-7) that form the core of the glycopeptide antibacterial agent, or (2) a mono- or polysaccharide group of the glycopeptide antibacterial agent.
- this term does not include any carbon atoms of the amino acids (AA 1-7) that form the core of the glycopeptide, or any carbon atoms that form the rings of a mono- or polysaccharide group attached to the glycopeptide core.
- “Pharmaceutically acceptable salt” means those salts which retain the biological effectiveness and properties of the parent compounds and which are not biologically or otherwise harmful at the dosage administered. Active agents employed in methods of the subject invention are capable of forming both acid and base salts by virtue of the presence of amino and carboxy groups respectively.
- Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally-occurring substituted amines, and cyclic amines, including isopropylamine, trimethyl amine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, and N-ethylpiperidine.
- carboxylic acid derivatives would be useful in the practice of this invention, for example carboxylic acid amides, including carboxamides, lower alkyl carboxamides, di(lower alkyl) carboxamides, and the like.
- Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like.
- Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
- treating means the treating or treatment of a disease or medical condition (such as a fungal infection) in a subject or patient, such as a mammal (particularly a human) that includes:
- therapeutically effective amount means an amount sufficient to effect treatment when administered to a subject or patient in need of treatment.
- the therapeutically effective amount will vary depending on the subject and disease state being treated, the severity of the affliction and the manner of administration, and may be determined routinely by one of ordinary skill in the art.
- antifungal amount means an amount sufficient to treat a fungal infection or medical condition.
- antibacterial amount means an amount sufficient to treat a bacterial infection or medical condition.
- polyene macrolide antifungal agents employed in this invention are a well known class of antifungal agents. See, for example, S. Zotchev, Current Medicinal Chemistry , (2003) 10(3):211-223. Such polyene macrolide antifungal agents are characterized by having a substituted macrolactone ring that has a polar hydrophilic head, opposed chromophore and polyol chains and a hydrophobic tail.
- the macrolactone ring is typically a 20 to 44 member macrolactone ring that contains a series of from about 2 to about 10, including 3 to 8, conjugated double bonds, and may be classified as a triene, tetraene, pentaene, hexaene, heptaene, or octaene, where the series of conjugated double bonds makes up the chromophore component of the compound.
- Such polyene macrolide antifungal agents typically contain a polar group, such as carbonyl, hydroxyl, or epoxide group and the like, located directly opposite the hydrophobic chromophore component.
- the polar head group includes a region of 8 carbon atoms of the macrolactone ring that are linked to the chromophore and form a hemiketal.
- an aminosugar e.g., mycosamine, perosamine, etc.
- a carboxyl group is bonded to the fourth carbon atom counter-clockwise from the chromophore region.
- derivatives of such compounds e.g., compounds in which modifications to one or more of the above moieties or groups have been made and which retain antifungal activity.
- Representative polyene macrolide antifungal agents of interest include, but are not limited to: tetraenes, such as nystatin, pimaricin and partricin; pentaenes, such as allomycin; methylpentaenes, such as filipin; carbonylpentaenes, such as mycoticin; hexaenes, such as cryptocidine; carbonylhexaenes, such as dermostatin; and heptaenes such as amphotericin B, candicidin D; or a pharmaceutically acceptable salt thereof.
- tetraenes such as nystatin, pimaricin and partricin
- pentaenes such as allomycin
- methylpentaenes such as filipin
- carbonylpentaenes such as mycoticin
- hexaenes such as cryptocidine
- carbonylhexaenes such as dermostatin
- polyene macrolide antifungal agents employed in this invention are commercially available or can be conventionally prepared by techniques known to one of skill in the art.
- representative patents describing various polyene macrolide antifungal agents and derivatives thereof, as well as the synthesis and preparation thereof include U.S. Pat. Nos. 2,797,183; 2,908,611; 4,812,312; 5,567,685; 5,606,038; 5,908,834; 5,965,158; 6,080,744; 6,121,244; and 6,413,537.
- Particular polyene macrolide antifungal agents of interest include amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin, candicidin and pimaricin. Of particular interest in certain embodiments are amphotericin B and nystatin. A particular polyene macrolide antifungal agent of interest is amphotericin B.
- glycopeptide antibacterial agents employed in this invention are a well known class of antibacterial agents. See, for example, Nicolaou et al., Angew. Chem. Int. Ed . (1999) 38:2096-2152; and Rao et al., Glycopeptides Classification, Occurrence, and Discovery. In Glycopeptide Antibiotics ; Ramakrishnan Nagarajan Ed.; Marcel Dekker, Inc.: New York, N.Y., 1994; Volume 63, pp 1-27.
- Glycopeptide antibacterial agents typically have a multi-ring peptide core comprising seven amino acids (i.e., AA-1 to AA-7) and at least 5 aromatic rings (i.e., rings A through E).
- the peptide core is optionally substituted with one or more saccharide groups.
- Type I structures contain aliphatic rings in AA-1 and AA-3.
- Type II, type III and type IV structures include aromatic side chains within these amino acids.
- type III and IV structures contain an extra F-O-G ring system.
- type IV compounds have a long fatty-acid chain attached to the sugar moiety.
- Type V compounds contain a tryptophan moiety linked to the central amino acid.
- glycopeptide antibacterial agents include those identified as A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850, A84575, AB-65, actaplanin, actinoidin, ardacin, avoparcin, azureomycin, balhimycin, chloroorientiein, chloropolysporin, dalbavancin, decaplanin, N-demethylvancomycin, eremomycin, galacardin, helvecardin, izupeptin, kibdelin, LL-AM374, mannopeptin, MM45289, MM47756, MM47761, MM49721, MM47766, MM55260, MM55266, MM55270, MM56597, MM56598, OA-7653, orenticin, oritivancin, parvodicin, ristocetin, ristomycin, synm
- glycopeptide antibacterial agents are disclosed in U.S. Pat. Nos. 4,639,433; 4,643,987; 4,497,802; 4,698,327; 5,591,714; 5,840,684; and 5,843,889; in EP 0 802 199; EP 0 801 075; EP 0 667 353; WO 97/28812; WO 97/38702; WO 98/52589; WO 98/52592; and in J. Amer. Chem. Soc., 1996, 118, 13107-13108 ; J. Amer. Chem. Soc., 1997, 119, 12041-12047; and J. Amer. Chem. Soc. 1994, 116, 4573-4590.
- glycopeptide antibacterial agents are those in which the N-terminal amino acid of a naturally-occurring glycopeptide antibacterial agent has been removed (i.e., a hexapeptide). Methods for preparing such hexapeptides are disclosed in U.S. Pat. No. 5,952,310; and P. M. Booth et al., J. Chem. Soc., Chem. Commun . (1987)1964-1965.
- glycopeptide antibacterial agent means a glycopeptide antibacterial agent that is produced by modifying a naturally-occurring glycopeptide antibacterial agent, e.g., through modification of the outer sphere of the parent compound; or through degradation and reassembly of the cyclopeptide core with incorporation, for example, of new amino acid components.
- synthetic glycopeptide antibacterial agent means any non-naturally occurring glycopeptide antibacterial agent, whether or not it is a modified naturally-occurring compound, i.e., a semi-synthetic compound.
- glycopeptide antibacterial agents of this invention When defining the glycopeptide antibacterial agents of this invention, the terms “type I,” “type II,” “type III,” “type IV,” “type V,” “semi-synthetic,” and “outer-sphere” are used as defined in the art (for example, as used the above cited Nicolaou et al., review).
- glycopeptide antibacterial agents used in this invention are those having a substituent comprising at least about 8 carbon atoms.
- the glycopeptide antibacterial agent may be a naturally-occurring glycopeptide antibacterial agent or a synthetic glycopeptide antibacterial agent (including a semi-synthetic glycopeptide antibacterial agent).
- the substituent comprising at least about 8 carbon atoms will contain from about 8 to about 24 carbon atoms, including from about 8 to about 20 carbon atoms, such as from about 8 to about 14 carbon atoms; and from 0 to about 5 heteroatoms selected from oxygen, nitrogen, sulfur or halo.
- the carbon atoms of such substituents may be linear or branched or may be joined to form aliphatic or aromatic rings, such as phenyl rings.
- the optional heteroatoms may interrupt the carbon chain, i.e., to form ethers, thioethers or amines, or may be substituents attached to the carbon chain, such as a chloro substituent.
- glycopeptide antibacterial agent is a compound of formula I:
- X 1 and X 2 are independently hydrogen or chloro
- R 1 is selected from the group consisting of:
- R e is C 2-8 alkylene
- R 2 and R 3 are hydroxy and the other is hydrogen;
- R 4 and R 5 are independently hydrogen or methyl
- R 6 is hydrogen or a group of formula (f):
- R 7 is hydrogen or a group of formula (g):
- n is an integer from 1 to 6;
- the glycopeptide antibacterial agent is a compound of formula I, where: X 1 and X 2 are both chloro; R 1 is —CH 2 CH 2 —NH—(CH 2 ) 9 CH 3 ; R 2 is hydroxy; R 3 is hydrogen; R 4 is methyl; R 5 is hydrogen; R 6 is hydrogen; and R 7 is —CH 2 —NH—CH 2 —P(O)(OH) 2 .
- This compound is known in the art as telavancin.
- the glycopeptide antibacterial agent is a compound of formula I, where: X 1 and X 2 are both chloro; R 1 is a group of the formula:
- R 2 is hydrogen; R 3 is hydroxy; R 4 is methyl; R 5 is hydrogen; R 6 is a group of formula (f); and R 7 is hydrogen.
- This compound is known in the art as oritavancin.
- the glycopeptide antibacterial agent is a compound of formula I, where: X 1 and X 2 are both chloro; R 1 is a group of the formula:
- R 2 is hydroxy; R 3 is H; R 4 is methyl; R 5 is hydrogen; R 6 is hydrogen; and R 7 is hydrogen.
- the glycopeptide antibacterial agent is dalbavancin.
- the glycopeptide antibacterial agent is a teicoplanin.
- teicoplanin include teicoplanin A 2 -1 to 5, i.e., includes one or more of teicoplanin A 2 -1; teicoplanin A 2 -2; teicoplanin A 2 -3; teicoplanin A 2 -4; and teicoplanin A 2 -5.
- the glycopeptide antibacterial agent is selected from telavancin, oritavancin, dalbavancin and teicoplanin; or a pharmaceutically acceptable salt thereof.
- derivatives of such compounds e.g., compounds in which modifications to one or more of the above moieties or groups have been made and which derivatives retain antibacterial activity.
- glycopeptide antibacterial agents are commercially available or can be conventionally prepared by techniques known to one of skill in the art.
- representative patents describing various glycopeptide compounds and derivatives thereof, as well as the synthesis or preparation thereof include U.S. Pat. Nos. 4,497,802; 4,639,433; 4,643,987; 4,698,327; 5,591,714; 5,750,509; 5,916,873; 5,919,756; 5,840,684; 5,840,684; 5,843,889; 5,977,062; and 6,444,786; as well as published U.S. Application Publication Nos. 2002/0022590 A1; 2003/008812 A1; 2003/0045457 A1; and 200310069391 A1.
- the present invention provides methods of administering a polyene macrolide antifungal agent to a subject in need of treatment.
- a feature of the present methods is that the polyene macrolide antifungal agent is administered to the subject in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- a polyene macrolide antifungal agent is administered to the subject together with an amount of a glycopeptide antibacterial agent.
- the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered sequentially, e.g., where the polyene macrolide antifungal agent is administered before or after the glycopeptide antibacterial agent.
- the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered simultaneously, e.g., where the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered at the same time as two separate formulations or are combined into a single composition that is administered to the subject. Regardless of whether the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered sequentially or simultaneously, the agents are considered to be administered together or in combination for purposes of the present invention.
- the amount of the polyene macrolide antifungal agent that is administered to the subject is a therapeutically effective amount to treat the subject for the condition afflicting the subject, e.g., for the fungal infection afflicting the subject. In many embodiments, this effective amount is one that is less than the amount which is effective when the polyene macrolide antifungal agent is not administered in combination with a glycopeptide antibacterial agent (i.e., in a control administration).
- the amount of polyene macrolide antifungal agent when administered according to this Invention, can typically be reduced by at least about 10% by weight per dose; in other cases, by at least about 20% by weight per dose; and in still other cases, by at least about 50% by weight per dose.
- the amount of polyene macrolide antifungal agent that Is administered to the subject ranges from about 0.1 mg/kg to about 25 mg/kg, such as from about 0.25 mg/kg to about 10 mg/kg, including from about 0.5 mg/kg to about 5 mg/kg.
- the amount of glycopeptide antibacterial agent that is administered to the subject is one that typically increases the efficacy of the polyene macrolide antifungal agent, where efficacy is considered to be increased if the amount of the polyene macrolide antifungal agent required to be effective is decreased by at least about 10% by weight per dose.
- the amount of glycopeptide agent administered to the subject is one that results in a synergistic increase in the efficacy of the polyene macrolide antifungal agent.
- synergistic increase is meant that the amount of glycopeptide antibacterial agent administered to the subject causes the efficacy of the co-administered polyene macrolide antifungal agent to increase synergistically.
- the amount of glycopeptide antibacterial agent that is administered is sufficient to result in a Functional Inhibitory Concentration Index (FICI) of ⁇ 0.7, including ⁇ 0.6, such as ⁇ 0.5, as determined using the MIC assay.
- FICI Functional Inhibitory Concentration Index
- the amount of glycopeptide antibacterial agent that is administered to the subject in any given dose ranges from about 0.1 mg/kg to about 50 mg/kg, such as from about 0.25 mg/kg to about 25 mg/kg, including from about 0.5 mg/kg to about 10 mg/kg.
- the combination of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent can be administered in a single daily dose or in multiple doses per day.
- the treatment regimen may require administration over extended periods of time, for example, for several days or for from one to six weeks.
- polyene macrolide antifungal agent and the glycopeptide antibacterial agent employed in this invention are typically formulated as a pharmaceutical composition suitable for administration to a subject in need of treatment.
- the polyene macrolide antifungal agent and the glycopeptide antibacterial agent may be formulated as separate pharmaceutical compositions for administration simultaneously or sequentially to a subject in need of treatment.
- such agents may be combined in a single pharmaceutical composition, i.e., one composition that includes both active agents.
- the polyene macrolide antifungal agent and the glycopeptide antibacterial agent will be formulated using conventional pharmaceutical compositions well known and previous described In the art for such agents.
- pharmaceutical compositions suitable for polyene macrolide antifungal agents are described in U.S. Pat. Nos. 4,822,777; 4,973,465; 5,077,057; 5,194,266; 5,567,685; 5,616,334; 5,965,158; and 6,413,537.
- Suitable amphotericin B formulations include, for example, Abelcet®, Amphotec®, Ambisome®, and Fungizone.
- pharmaceutical compositions suitable for glycopeptide antibacterial agents are described in U.S. Pat. Nos. 5,977,062 and 6,635,618; EP 0 667 353; EP 0 525 499; and WO01/82971.
- this invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising a polyene macrolide antifungal agent; a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms; and a pharmaceutically acceptable carrier, excipient or vehicle.
- the polyene macrolide antifungal agent and/or the glycopeptide antibacterial agent can be admixed with conventional pharmaceutical carriers and excipients (i.e., vehicles) and used in the form of aqueous solutions, tablets, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such pharmaceutical compositions generally contain, in certain embodiments, from about 0.1 to about 90% by weight of the active compound, and more generally from about 1 to about 30% by weight of the active compound.
- compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, dextrose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid.
- Disintegrators commonly used in the formulations of this Invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
- a liquid composition will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example, ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting agent, flavoring or coloring agent.
- a suitable liquid carrier for example, ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting agent, flavoring or coloring agent.
- a liquid formulation can be prepared from a reconstitutable powder.
- a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstituted with water to form a suspension; and a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid compositions.
- suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose, microcrystalline cellulose and binders, for example, polyvinylpyrrolidone.
- the tablet can also be provided with a color film coating, or color included as part of the carrier(s).
- active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures, for example, by incorporation of active compound and excipients into a hard gelatin capsule.
- a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example, liquid paraffin or fractionated coconut oil can be prepared and filled into a soft gelatin capsule.
- Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.
- Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
- Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.
- the compounds of the invention and their pharmaceutically acceptable salts that are active when given parenterally can be formulated for intramuscular, intrathecal, or intravenous administration.
- a typical composition for intramuscular or intrathecal administration will be of a suspension or solution of active ingredient in an oil, for example, arachis oil or sesame oil.
- a typical composition for intravenous or intrathecal administration will be a sterile isotonic aqueous solution containing, for example, active ingredient and dextrose or sodium chloride, or a mixture of dextrose and sodium chloride.
- Other examples are lactated Ringer's injection, lactated Ringers plus dextrose injection, Normosol-M and dextrose, Isolyte E, acylated Ringer's injection, and the like.
- a co-solvent for example, polyethylene glycol
- a chelating agent for example, ethylenediamine tetraacetic acid
- an anti-oxidant for example, sodium metabisulphite
- the solution can be freeze dried and then reconstituted with a suitable solvent just prior to administration.
- the compounds of the invention and their pharmaceutically acceptable salts which are active on rectal administration can be formulated as suppositories.
- a typical suppository formulation will generally consist of active ingredient with a binding and/or lubricating agent such as a gelatin or cocoa butter or other low melting vegetable or synthetic wax or fat.
- transdermal compositions or transdermal delivery devices (“patches”).
- Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive.
- transdermal patches may be used to provide continuous or discontinuous Infusion of the compounds of the present invention in controlled amounts.
- the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, for example, U.S. Pat. No. 5,023,252, issued Jun. 11, 1991.
- patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- the pharmaceutical composition containing the glycopeptide antibacterial agent will further comprise a cyclodextrin compound.
- the glycopeptide antibacterial agent for example, in the form a pharmaceutically acceptable salt, can be admixed with an aqueous cyclodextrin solution to form a pharmaceutical composition.
- Such pharmaceutical compositions will typically contain from about 1 to about 40 weight percent of the cyclodextrin and an effective amount of the glycopeptide antibacterial agent.
- the cyclodextrin employed in the pharmaceutical compositions of this invention is hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl ether ⁇ -cyclodextrin.
- the cyclodextrin is hydroxypropyl- ⁇ -cyclodextrin. In certain embodiments, the cyclodextrin will comprise about 1 to 40 weight percent; such as about 2 to 30 weight percent; including about 5 to 15 weight percent, of the formulation. In an embodiment, the aqueous cyclodextrin solution further comprises dextrose, e.g., about 5% dextrose.
- the pharmaceutical composition may contain other pharmaceutically acceptable components, such a buffers, surfactants, antioxidants, viscosity modifying agents, preservatives and the like.
- these components are well known in the art. See, for example, U.S. Pat. No. 5,985,310.
- kits and systems for use in practicing the methods described herein may include one or more pharmaceutical formulations, which include one or both of the polyene macrolide antifungal agent and the glycopeptide antibacterial agent.
- the kits may include a single pharmaceutical composition, present as one or more unit dosages, where the composition comprises both the polyene macrolide antifungal agent and the glycopeptide antibacterial agent.
- the kits may include two or more separate pharmaceutical compositions, each containing either a polyene macrolide antifungal agent or a glycopeptide antibacterial agent.
- kits may further include instructions for practicing the methods of this invention.
- These instructions may be present in the kits in a variety of forms, one or more of which may be present in the kit.
- One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc.
- Yet another means would be a computer readable medium, e.g., diskette, CD, etc., on which the information has been recorded.
- Yet another means that may be present is a website address which may be used via the internet to access the information at a removed site. Any convenient means for providing instructions may be present in the kits.
- system means a collection of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent, present in a single or disparate composition, that are brought together for the purpose of practicing the methods of this invention.
- polyene macrolide antifungal agent and glycopeptide antibacterial agent dosage forms brought together and co-administered to a subject in need of treatment, according to the present invention, are a system according to the present invention.
- the methods, compositions, kits and systems of this invention are useful for treating a subject having a fungal infection or medical condition which is caused by a pathogenic organism, e.g., a fungus, that is inhibited by or treatable with a polyene macrolide antifungal agent.
- a pathogenic organism e.g., a fungus
- the subject may already have a fungal Infection or the combination of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent may be used in prophylactic therapy and empirical therapy where treatment is initiated prior to the identification of the causative pathogen.
- a variety of subjects or patients or hosts are treatable using the methods, compositions, kits and systems of the present invention.
- subjects are “mammals” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys).
- the subject or patient is a human.
- Candida spp. such as C. albicans, C. krusei, C. glabrata, C. tropicalis, C. parapsilosis, C. guilliermorulii, C. haemulonii, C. iusitaniae, C. neoformans, C. norvegensis, C. viswanathii , and C. kefyr ; Hyaline molds, such as Aspergillus fumigatus, A. flavus, A. niger, F. moniliforme, Geotricium candidum; Histoplasma capsulatum (var.
- capsulatum Coccidioides immitis, Cryptococcus neoformans (var. neoformans , and var. gattii ), C. bidus, C. laurentii , and C. fusarium , as well as Mucormycotic organisms, e.g., Zygomycetes spp.; such as Rhizopus oryzae, R. micropsorus, R. pusillus, Cunninghamelle bertholletiae, Saksenaea vasiformis, Mucor circinelloides, M. ramosissimus, Absidia corymbifera, Apophysomyces elegans, Cokeromyces recurvatus , and Syncephalastrum racemosum.
- the present invention provides a method of treating a fungal infection in a subject, the method comprising administering to the subject an antifungal amount, e.g., an amount effective to treat the subject, of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent as further described herein.
- an antifungal amount e.g., an amount effective to treat the subject, of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent as further described herein.
- compositions of this invention may also be used for coating of medical instruments or implants, agricultural applications, etc. as described further, for example, in U.S. Pat. No. 6,541,506.
- the subject being treated suffers from both a fungal infection and a bacterial infection, where the bacterial infection is responsive to the glycopeptide antibacterial agent employed in this invention.
- this invention also provides a method for treating a bacterial infection and a fungal infection in a subject in need of treatment, the method comprising administering to the subject an antifungal amount of a polyene macrolide antifungal agent and an antibacterial amount of a glycopeptide antibacterial agent as further described herein.
- Representative bacterial infections or medical conditions that may be treated include those caused by the following staphylococci, including methicillin-resistant staphylococci; enterococci, including vancomycin-resistant enterococci (VRE); severe staphylococcal infections, such as staphylococcal endocarditis and staphylococcal septicemia; and the like.
- staphylococci including methicillin-resistant staphylococci
- enterococci including vancomycin-resistant enterococci (VRE)
- severe staphylococcal infections such as staphylococcal endocarditis and staphylococcal septicemia; and the like.
- MOPS 3-[N-Morpholino]propanesulfonic acid
- the following assay was used to determine the minimum inhibitory concentration (MIC) and fractional inhibitory concentration index (FICI) for combinations of an antifungal agent and a glycopeptide antibacterial agent.
- MIC minimum inhibitory concentration
- FICI fractional inhibitory concentration index
- This assay and methods for calculating FICI are well known in the art. See, for example, Eliopoulos, E. G. and R. Moellering, Jr. “Antimicrobial Combinations” in Antibiotics in Laboratory Medicine , edited by V. Lorian, 4 th Ed., Williams & Wilkins, Baltimore, Md., pp.
- FICI values are typically classified as followings:
- a combination of an antifungal agent and a glycopeptide antibacterial agent was considered to be more effective than the antifungal agent alone, if the combined compounds demonstrated either a calculated FICI of less than or equal to about 0.5 or a decrease of the antifungal MIC by at least a one-fold dilution factor.
- the fungal strains used in this assay are highly infectious. Standard safety measures, such as use of disposable screw cap tubes and use of safety masks, were strictly followed. All work was conducted in a Biosafety Level 2 cabinet. All materials and equipment (e.g., pipettors and Incubators) were decontaminated between experiments.
- the fungal strains used in this assay were obtained from the American Type Culture Collection (ATCC), Manassas, Va. In the table below, the ATCC deposit number for each strain is indicated under the column heading “ATCC”. Other strains can be used if desired.
- ATCC American Type Culture Collection
- Other strains can be used if desired.
- Candida albicans 24433 Nail infection Candida albicans 90028 Blood, Iowa Candida parapsilosis 22019 Case of spruce, Puerto Rico Candida parapsilosis 90018 Blood, Virginia Candida tropicalis 750
- Candida krusei 32672 Human, New Zealand Candida glabrata 200918 Human tongue, Santa Rosa, California Cryptococcus neoformans 14117 Human meningitis Cryptococcus neoformans 56991 Human, Zaire
- NCCLS 2003 “Reference Method for Broth Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard” (NCCLS document M7-A6); NCCLS 2002, “Reference Method for Broth Dilution Antifungal Susceptibility Tests of Filamentous Fungi that Grow Aerobically; Approved Standard” (NCCLS document M38-A); and NCCLS 2002 “Reference Method for Broth Dilution Antifungal Susceptibility Tests of Yeast; Approved Standards-2nd Edition” (NCCLS document M27-A2).
- R 1 and R 7 are as defined as follows:
- R 1 R 7 Compound 1 —CH 2 CH 2 —NH—(CH 2 ) 9 CH 3 —CH 2 —NH—CH 2 —P(O)(OH) 2 Compound 2 —CH 2 CH 2 —NH—(CH 2 ) 9 CH 3 —H Compound 3 —H
- Compounds 1 and 2 were prepared as described in Example 2 of U.S. Provisional Appl. No. 2002/0022590 A1, published on Feb. 21, 2002.
- Compound 3 was prepared from vancomycin and 4-(4′-chlorophenyl)benzaldehyde using the procedures described in U.S. Pat. No. 6,392,012, issued on May 21, 2002.
- Vancomycin was purchased from Sigma-Aldrich (St. Louis, Mo.). Telcoplanin was purchased from a pharmacy in Germany as i.v. infusion Targocid®.
- Amphotericin B and miconazole were purchased from U.S. Pharmacopeia (Rockville, Md.). Fluconazole and voriconazole (formulated as Vfend®) were purchased from Peninsula Pharmacy (Burlingame, Calif.). Fluconazole was purchased as Diflucan® (oral formulation) and purified prior to use.
- a 2-fold dilution 100 ⁇ final concentration master plate was prepared using a 96-well U-shape microtiter plate and an appropriate solvent.
- a microtiter plate is divided into “columns” in which each well in the column contains the same amount of an antifungal agent (Compound A) being diluted along the x-axis, and “rows” in which each well in the row contains the same amount of a glycopeptide antibacterial agent (Compound B) being diluted on the y-axis. Also included is a row (or column) for Compound A or B alone.
- the dilutions used in the checkerboard are exponential (by powers of two). The result is that each well in the microtiter plate contains a unique concentration of the two compounds being tested.
- a matrix 2 ⁇ final concentration was performed by transferring 30 ⁇ L of 100 ⁇ Compound A and Compound B into a 1,440 ⁇ L RPMI in deep wells (one deep well per drug combination). After mixing, 100 ⁇ L of 2 ⁇ drug combinations were distributed into 96-well microtiter plates.
- Compound A was diluted from Column 1 starting at 1,600 ⁇ g/mL to Column 11 (1.6 ⁇ g/mL).
- Wells in Column 1 contained a final concentration (after inoculum was added) of 16 ⁇ g/mL of Compound A;
- wells in Column 2 contained a final concentration of 8 ⁇ g/mL of Compound A;
- wells in Column 3 contained a final concentration of 4 ⁇ g/mL of Compound A; etc.
- Compound A was not added to Column 12, so Column 12 contained only Compound B.
- Compound B was diluted from row A starting at 6,400 ⁇ g/mL down to row G (100 ⁇ g/mL).
- Wells in Row A contained a final concentration of 64 ⁇ g/mL of Compound B;
- Row B contained a final concentration of 32 ⁇ g/mL of Compound B;
- Row C contained a final concentration of 16 ⁇ g/mL of Compound B; etc.
- Compound B was not added to Row H, so Row H only contained Compound A.
- Compound Compound A ( ⁇ g/mL final) Compound B 16 8 4 2 1 0.5 0.25 0.125 0.063 0.031 0.015 0 B ( ⁇ g/mL final) 1 2 3 4 5 6 7 8 9 10 11 12 ( ⁇ g/mL final) 64 A A 64 32 B B 32 16 C C 16 8 D D 8 4 E E 4 2 F F 2 1 G G 1 0 H H 0 1 2 3 4 5 6 7 8 9 10 11 12 16 8 4 2 1 0.5 0.25 0.125 0.063 0.031 0.015 0
- the MIC of the glycopeptide antibacterial agent alone was >64 ⁇ g/mL.
- a standard MIC assay using NCCLS protocols was performed with an extended concentration range of from 256 ⁇ g/mL to 0.25 ⁇ g/mL.
- the MIC of the glycopeptide antibacterial agent determined from this experiment was used in FIC calculations. If the MIC of the glycopeptide antibacterial agent was >256 ⁇ g/mL, FIC of the compound was calculated using 256 ⁇ g/mL as the closest value to the true MIC.
- RPMI-1640 without sodium bicarbonate media (GIBCO-BRL, Carlsbad, Calif.), an enriched media formulated for mammalian cells, was used according to the NCCLS guidelines for yeast and filamentous fungi susceptibility testing.
- the medium was buffered with 0.165 M 3-[N-Morpholino]propanesulfonic acid (MOPS) supplemented with 20 g/L glucose and pH adjusted to 7.0 with hydrogen chloride.
- MOPS N-Morpholino]propanesulfonic acid
- SDA Sabouraud Dextrose Agar
- PDA Potato Dextrose Agar
- Yeast cultures were started from ⁇ 80° C. frozen stock streaked on SDA slants and incubated at 35° C. under aerobic conditions for 24 h. The slants were kept in the refrigerator for up to 2 weeks and used regularly as a starting culture. About 24 to 48 h before each assay was run, yeasts were streaked on SDA plates for isolated colonies. To prepare the inoculum, from one to four colonies were resuspended in 5 mL of saline, and vortexed for 15 sec.
- Molds started from ⁇ 80° C. frozen stocks were spotted in the center of the PDA plates. The plates were incubated at 35° C. for 7 days to induce conidiospores and sporangiospores.
- Fast growing molds i.e., Fusarium spp. and Rhizopus spp.
- the mold spores were resuspended in saline (avoiding aerosol formation), then vortexed for 15 sec, and the hypheal particles were allowed to settle for 5 to 10 min.
- the initial optical density (OD) at 530 nm of the vortexed cells suspended in saline was less than 0.5 as measured using a SmartSpec 3000 spectrophotometer (BioRAD, Hercules, Calif.).
- the optical density (OD) of the suspension was adjusted to 0.11 in saline to provide ⁇ 0.4 ⁇ 10 6 CFU/mL.
- the culture was diluted 1:1,000 for yeasts and 1:50 for molds in RPMI media (GIBCO-BRL) to get a 2 ⁇ final inoculum.
- the inoculum size calculated from the colony count on the validation plate was outside the expected range of 0.5 ⁇ 10 3 to 2.5 ⁇ 10 3 CFU/mL (yeasts) and 0.4 ⁇ 10 4 to 5 ⁇ 10 4 CFU/mL (molds), the entire assay test was redone.
- MIC minimum inhibitory concentration
- FIC fractional inhibitory concentration
- RPMI media was clear and transparent at Inoculation. When no turbidity was observed, the growth of the inoculum cells was inhibited, and the well remained clear.
- the minimum inhibitory concentration (MIC) of a compound i.e., the minimum inhibitory concentration of compound A (MIC A ), is the concentration of compound A at which no growth is observed.
- Fractional Inhibitory Concentration was calculated using the concentration that reduced the antifungal compound MIC by at least a 2-fold dilution factor (i.e., “concentration of compound in synergistic well”).
- concentration of compound in synergistic well The Fractional Inhibitory Concentration for compound A, FIC(A), is equal to the concentration of compound A in synergistic well divided by MIC(A).
- FIC(B) the concentration of compound B in synergistic well divided by MIC(B).
- the Fractional Inhibitory Concentration Index (FICI) is equal to the sum of FIC(A)+FIC(B).
- FIC ⁇ ( A ) concentration ⁇ ⁇ ( A ) ⁇ ⁇ in ⁇ ⁇ synergistic ⁇ ⁇ well MIC ⁇ ( A )
- FIC ⁇ ( B ) concentration ⁇ ⁇ ( B ) ⁇ ⁇ in ⁇ ⁇ synergistic ⁇ ⁇ well MIC ⁇ ( B )
- FICI FIC ⁇ ( A ) + FIC ⁇ ( B )
- the assay was repeated at least twice to show reproducibility. Because MICs have an inherent 50% error associated with the assay, no average or statistical analysis was performed. FICs however are not affected by the MIC variability.
- the interactions of the combined compounds can be expressed as a graph in which antifungal MIC ( ⁇ g/mL) is plotted on the Y-axis as a function of antibacterial concentration ( ⁇ g/mL) which is plotted on X-axis.
- antifungal MIC ⁇ g/mL
- antibacterial concentration ⁇ g/mL
- the synergistic interaction of the two combined compounds can alternatively be calculated or validated with other assays, such as a time-kill synergy assay as discussed in Eliopoulos, E. G. and R. Moellering, Jr.
- vancomycin and amphotericin B were not synergistic or additive.
- azole antifungal agents did not show a synergistic or additive effect when combined with the glycopeptide antibacterial agents.
- the present invention provides significant advantages for administering a polyene macrolide antifungal agent to a subject in need thereof. More specifically, by administering such a polyene macrolide antifungal agent in combination with a specified glycopeptide antibacterial agent, the efficacy of the polyene macrolide antifungal agent is significantly increased thereby allowing for reduced dosages (e.g., to reduce or eliminate toxicity), quicker treatment protocols, etc.
Abstract
This invention is directed to methods of administering a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms. The invention is also directed to methods of using a polyene macrolide antifungal agent in combination with a specified glycopeptide antibacterial agent to treat fungal infections; and to compositions, kits and systems comprising a polyene macrolide antifungal agent and a specified glycopeptide antibacterial agent.
Description
- This application claims the benefit of U.S. Provisional Application No. 60/473,523, filed May 27, 2003; the entire disclosure of which is incorporated herein by reference in its entirety.
- 1. Field of the Invention
- This invention relates to the use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent. More specifically, this invention relates to methods of using a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent to treat fungal infections; and to compositions, kits and systems comprising a polyene macrolide antifungal agent and a glycopeptide antibacterial agent.
- 2. State of the Art
- Polyene macrolide antifungal agents, such as amphotericin B and nystatin, are well known in the art for the treatment of fungal Infections. However, when administered parenterally, such polyene macrolide antifungal agents have a number of serious side effects including nephrotoxicity. These side effects limit the amount of the polyene macrolide antifungal agent that can be administered safely to a patient and thus, such side effects limit the effectiveness of these antifungal agents.
- Accordingly, a need exists for new methods of administering a polyene macrolide antifungal agent that reduce the side effects of such agents. In particular, a need exists for new methods and compositions that enhance the efficacy of such antifungal agents thereby permitting a reduced amount of such antifungal agents to be administered.
- The present invention provides a novel method of administering a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent. Surprisingly, it has now been discovered that, when a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms is administered in combination with a polyene macrolide antifungal agent, the efficacy of the polyene macrolide antifungal agent is substantially increased. Accordingly, when used in combination with such a glycopeptide antibacterial agent, the amount of polyene macrolide antifungal agent needed to treat a fungal infection is reduced thereby resulting in fewer side effects.
- Accordingly, In one of its method aspects, this invention provides a method for administering a polyene macrolide antifungal agent to a subject, the method comprising administering to the subject a polyene macrolide antifungal agent and a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- In another of its method aspects, this invention provides a method for treating a fungal infection in a subject, the method comprising administering to the subject an antifungal amount of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- In yet another of its method aspects, this Invention provides a method for increasing the efficacy of a polyene macrolide antifungal agent, the method comprising administering the polyene macrolide antifungal agent to a subject in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- In one of its composition aspects, this invention provides a pharmaceutical composition comprising:
- (a) a polyene macrolide antifungal agent;
- (b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms; and
- (c) a pharmaceutically acceptable carrier.
- In another aspect, this invention provides a kit comprising:
- (a) a polyene macrolide antifungal agent; and
- (b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- In one embodiment, the kit further comprises instructions for administering the antifungal and antibacterial agents to a subject in need of treatment.
- In yet another aspect, this invention provides a system for treating a fungal infection in a subject, the system comprising:
- (a) a polyene macrolide antifungal agent; and
- (b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- This invention is also directed to the use of:
- (a) a polyene macrolide antifungal agent; and
- (b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms;
- in the manufacture of a medicament for the treatment of a fungal infection.
- In particular, this invention is directed to the use of a polyene macrolide antifungal agent in the manufacture of a medicament for co-administration with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms for the treatment of a fungal infection.
- Moreover, this invention is directed to the use of a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms In the manufacture of a medicament for co-administration with a polyene macrolide antifungal agent for the treatment of a fungal infection.
- In yet another of its aspects, this invention provides a combination comprising:
- (a) a polyene macrolide antifungal agent; and
- (b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- The present invention provides a novel method of administering a polyene macrolide antifungal agent to a subject in need of treatment. A feature of the present invention is that the polyene macrolide antifungal agent is administered to the subject in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms. The antifungal and antibacterial agents may be administered sequentially or simultaneously; and may be in the same or separate formulations. Also provided are compositions, including pharmaceutical compositions, kits and systems, comprising a polyene macrolide antifungal agent and a glycopeptide antibacterial agent as defined herein.
- Before the present invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described herein, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed herein is for the purpose of describing particular embodiments and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.
- In this specification and the appended claims, the singular forms “a,” “an” and “the” include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
- When describing the compounds, compositions, methods, kits, systems and processes of this invention, the following terms have the following meanings unless otherwise indicated.
- The term “alkyl” means a monovalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkyl groups typically contain from 1 to 15 carbon atoms. Representative alkyl groups include, by way of example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
- When a specific number of carbon atoms is intended for a particular term used herein, the number of carbon atoms is shown preceding the term. For example, the term “C8-12 alkyl” means an alkyl group having from 8 to 12 carbon atoms.
- The term “alkylene” means a divalent saturated hydrocarbon group which may be linear or branched. Unless otherwise defined, such alkylene groups typically contain from 1 to 10 carbon atoms. Representative alkylene groups include, by way of example, methylene, ethane-1,2-diyl (“ethylene”), propane-1,2-diyl, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl and the like.
- The term “alkoxy” means a monovalent group of the formula (alkyl)-O—, where alkyl is as defined herein. Representative alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy and the like.
- The term “alkenyl” means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon double bonds. Unless otherwise defined, such alkenyl groups typically contain from 2 to 15 carbon atoms. Representative alkenyl groups include, by way of example, ethenyl, n-propenyl, isopropenyl, n-but-2-enyl, n-hex-3-enyl and the like.
- The term “alkynyl” means a monovalent unsaturated hydrocarbon group which may be linear or branched and which has at least one, and typically 1, 2 or 3, carbon-carbon triple bonds. Unless otherwise defined, such alkynyl groups typically contain from 2 to 15 carbon atoms. Representative alkynyl groups include, by way of example, ethynyl, n-propynyl, n-but-2-ynyl, n-hex-3-ynyl and the like.
- The term “halo” means fluoro, chloro, bromo and iodo.
- The term “saccharide group” means an oxidized, reduced or substituted saccharide monoradical covalently attached to the glycopeptide or other compound via any atom of the saccharide moiety, e.g., via the aglycone carbon atom. The term includes amino-containing saccharide groups. Representative saccharide include, by way of illustration, hexoses such as D-glucose, D-mannose, D-xylose, Dgalactose, vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, D-glucamine, N-methyl-D-glucamine, D-glucuronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, sialyic acid, iduronic acid, L-fucose, and the like; pentoses such as D-ribose or D-arabinose; ketoses such as D-ribulose or D-fructose; disaccharides such as 2-O-(α-L-vancosaminyl) β-D-glucopyranose, 2-O-(3-desmethyl-α-L-vancosaminyl)-β-D-glucopyranose, sucrose, lactose, or maltose; derivatives such as acetals, amines, acylated, sulfated and phosphorylated sugars; oligosaccharides having from 2 to 10 saccharide units. For the purposes of this definition, the saccharide can be either in its open or in cyclic form (i.e., the pyranose form for hexoses).
- The term “amino-containing saccharide group” means a saccharide group having an amino substituent. Representative amino-containing saccharides include L-vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, N-methyl-D-glucamine and the like.
- A “substituent comprising at least 8 carbon atoms” means any substituent having at least 8 carbon atoms which substituent may also contain other atoms such as oxygen, nitrogen, sulfur or halo; or combinations thereof. When attached to a glycopeptide antibacterial agent, such a substituent is attached to either (1) the amino acids (AA 1-7) that form the core of the glycopeptide antibacterial agent, or (2) a mono- or polysaccharide group of the glycopeptide antibacterial agent. When determining the number of carbon atoms in the substituent, this term does not include any carbon atoms of the amino acids (AA 1-7) that form the core of the glycopeptide, or any carbon atoms that form the rings of a mono- or polysaccharide group attached to the glycopeptide core.
- “Pharmaceutically acceptable salt” means those salts which retain the biological effectiveness and properties of the parent compounds and which are not biologically or otherwise harmful at the dosage administered. Active agents employed in methods of the subject invention are capable of forming both acid and base salts by virtue of the presence of amino and carboxy groups respectively.
- Pharmaceutically acceptable base addition salts may be prepared from inorganic and organic bases. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally-occurring substituted amines, and cyclic amines, including isopropylamine, trimethyl amine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, and N-ethylpiperidine. It should also be understood that other carboxylic acid derivatives would be useful in the practice of this invention, for example carboxylic acid amides, including carboxamides, lower alkyl carboxamides, di(lower alkyl) carboxamides, and the like.
- Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
- The term “treating” or “treatment” as used herein means the treating or treatment of a disease or medical condition (such as a fungal infection) in a subject or patient, such as a mammal (particularly a human) that includes:
-
- (a) preventing the disease or medical condition from occurring, i.e., prophylactic treatment of a patient;
- (b) ameliorating the disease or medical condition, i.e., eliminating or causing regression of the disease or medical condition in a patient;
- (c) suppressing the disease or medical condition, i.e., slowing or arresting the development of the disease or medical condition in a patient; or
- (d) alleviating the symptoms of the disease or medical condition in a patient.
- The term “therapeutically effective amount” means an amount sufficient to effect treatment when administered to a subject or patient in need of treatment. The therapeutically effective amount will vary depending on the subject and disease state being treated, the severity of the affliction and the manner of administration, and may be determined routinely by one of ordinary skill in the art.
- The term “antifungal amount” means an amount sufficient to treat a fungal infection or medical condition.
- The term “antibacterial amount” means an amount sufficient to treat a bacterial infection or medical condition.
- The polyene macrolide antifungal agents employed in this invention are a well known class of antifungal agents. See, for example, S. Zotchev, Current Medicinal Chemistry, (2003) 10(3):211-223. Such polyene macrolide antifungal agents are characterized by having a substituted macrolactone ring that has a polar hydrophilic head, opposed chromophore and polyol chains and a hydrophobic tail. The macrolactone ring is typically a 20 to 44 member macrolactone ring that contains a series of from about 2 to about 10, including 3 to 8, conjugated double bonds, and may be classified as a triene, tetraene, pentaene, hexaene, heptaene, or octaene, where the series of conjugated double bonds makes up the chromophore component of the compound. Such polyene macrolide antifungal agents typically contain a polar group, such as carbonyl, hydroxyl, or epoxide group and the like, located directly opposite the hydrophobic chromophore component. In many embodiments, the polar head group includes a region of 8 carbon atoms of the macrolactone ring that are linked to the chromophore and form a hemiketal. In certain embodiments, an aminosugar, e.g., mycosamine, perosamine, etc., is linked via a glycosidic bond to the first carbon atom after the chromophore region (in the counter-clockwise direction). In certain embodiments, a carboxyl group is bonded to the fourth carbon atom counter-clockwise from the chromophore region. Also of interest are derivatives of such compounds, e.g., compounds in which modifications to one or more of the above moieties or groups have been made and which retain antifungal activity.
- Representative polyene macrolide antifungal agents of interest include, but are not limited to: tetraenes, such as nystatin, pimaricin and partricin; pentaenes, such as allomycin; methylpentaenes, such as filipin; carbonylpentaenes, such as mycoticin; hexaenes, such as cryptocidine; carbonylhexaenes, such as dermostatin; and heptaenes such as amphotericin B, candicidin D; or a pharmaceutically acceptable salt thereof.
- The polyene macrolide antifungal agents employed in this invention are commercially available or can be conventionally prepared by techniques known to one of skill in the art. For example, representative patents describing various polyene macrolide antifungal agents and derivatives thereof, as well as the synthesis and preparation thereof, include U.S. Pat. Nos. 2,797,183; 2,908,611; 4,812,312; 5,567,685; 5,606,038; 5,908,834; 5,965,158; 6,080,744; 6,121,244; and 6,413,537.
- Particular polyene macrolide antifungal agents of interest include amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin, candicidin and pimaricin. Of particular interest in certain embodiments are amphotericin B and nystatin. A particular polyene macrolide antifungal agent of interest is amphotericin B.
- The glycopeptide antibacterial agents employed in this invention are a well known class of antibacterial agents. See, for example, Nicolaou et al., Angew. Chem. Int. Ed. (1999) 38:2096-2152; and Rao et al., Glycopeptides Classification, Occurrence, and Discovery. In Glycopeptide Antibiotics; Ramakrishnan Nagarajan Ed.; Marcel Dekker, Inc.: New York, N.Y., 1994; Volume 63, pp 1-27.
- Glycopeptide antibacterial agents typically have a multi-ring peptide core comprising seven amino acids (i.e., AA-1 to AA-7) and at least 5 aromatic rings (i.e., rings A through E). The peptide core is optionally substituted with one or more saccharide groups. Type I structures contain aliphatic rings in AA-1 and AA-3. Type II, type III and type IV structures include aromatic side chains within these amino acids. Furthermore, type III and IV structures contain an extra F-O-G ring system. In addition, type IV compounds have a long fatty-acid chain attached to the sugar moiety. Type V compounds contain a tryptophan moiety linked to the central amino acid.
- Examples of glycopeptide antibacterial agents include those identified as A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850, A84575, AB-65, actaplanin, actinoidin, ardacin, avoparcin, azureomycin, balhimycin, chloroorientiein, chloropolysporin, dalbavancin, decaplanin, N-demethylvancomycin, eremomycin, galacardin, helvecardin, izupeptin, kibdelin, LL-AM374, mannopeptin, MM45289, MM47756, MM47761, MM49721, MM47766, MM55260, MM55266, MM55270, MM56597, MM56598, OA-7653, orenticin, oritivancin, parvodicin, ristocetin, ristomycin, synmonicin, teicoplanin, telavancin, UK-68597, UK-69542, UK-72051, vancomycin, and the like.
- Additional examples of glycopeptide antibacterial agents are disclosed in U.S. Pat. Nos. 4,639,433; 4,643,987; 4,497,802; 4,698,327; 5,591,714; 5,840,684; and 5,843,889; in EP 0 802 199; EP 0 801 075; EP 0 667 353; WO 97/28812; WO 97/38702; WO 98/52589; WO 98/52592; and in J. Amer. Chem. Soc., 1996, 118, 13107-13108; J. Amer. Chem. Soc., 1997, 119, 12041-12047; and J. Amer. Chem. Soc. 1994, 116, 4573-4590.
- Another group of glycopeptide antibacterial agents are those in which the N-terminal amino acid of a naturally-occurring glycopeptide antibacterial agent has been removed (i.e., a hexapeptide). Methods for preparing such hexapeptides are disclosed in U.S. Pat. No. 5,952,310; and P. M. Booth et al., J. Chem. Soc., Chem. Commun. (1987)1964-1965.
- The term “semi-synthetic glycopeptide antibacterial agent” means a glycopeptide antibacterial agent that is produced by modifying a naturally-occurring glycopeptide antibacterial agent, e.g., through modification of the outer sphere of the parent compound; or through degradation and reassembly of the cyclopeptide core with incorporation, for example, of new amino acid components. The term “synthetic glycopeptide antibacterial agent” means any non-naturally occurring glycopeptide antibacterial agent, whether or not it is a modified naturally-occurring compound, i.e., a semi-synthetic compound. When defining the glycopeptide antibacterial agents of this invention, the terms “type I,” “type II,” “type III,” “type IV,” “type V,” “semi-synthetic,” and “outer-sphere” are used as defined in the art (for example, as used the above cited Nicolaou et al., review).
- The particular glycopeptide antibacterial agents used in this invention are those having a substituent comprising at least about 8 carbon atoms. In this regard, the glycopeptide antibacterial agent may be a naturally-occurring glycopeptide antibacterial agent or a synthetic glycopeptide antibacterial agent (including a semi-synthetic glycopeptide antibacterial agent).
- Typically, the substituent comprising at least about 8 carbon atoms will contain from about 8 to about 24 carbon atoms, including from about 8 to about 20 carbon atoms, such as from about 8 to about 14 carbon atoms; and from 0 to about 5 heteroatoms selected from oxygen, nitrogen, sulfur or halo. The carbon atoms of such substituents may be linear or branched or may be joined to form aliphatic or aromatic rings, such as phenyl rings. The optional heteroatoms may interrupt the carbon chain, i.e., to form ethers, thioethers or amines, or may be substituents attached to the carbon chain, such as a chloro substituent.
- In certain embodiments, the glycopeptide antibacterial agent is a compound of formula I:
- wherein
- X1 and X2 are independently hydrogen or chloro;
- R1 is selected from the group consisting of:
-
- (a) —Ra;
- (b) —C(O)—Rb;
- (c) —Rc—W1;
- (d) —C(O)—Rd W2; and
- (e) —Re—Y—Rf;
- where
-
- Ra and Rb are independently C8-14 alkyl, C8-14 alkenyl or C8-14 alkynyl;
- Rc and Rd are independently C1-8 alkylene;
- Re is C2-8 alkylene;
-
- Rf is C1-12 alkyl, C2-12 alkenyl or C2-12 alkynyl;
- W1 and W2 are independently phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, -(phenyl), —CH2-(phenyl), —O-(phenyl), and —O—CH2— (phenyl); wherein each -(phenyl) group is optionally substituted with 1 or 2 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy and halo;
- Y is O, S or NH;
- and provided that R1 comprises at least 8 carbon atoms;
- one of R2 and R3 is hydroxy and the other is hydrogen;
- R4 and R5 are independently hydrogen or methyl;
- R6 is hydrogen or a group of formula (f):
- R7 is hydrogen or a group of formula (g):
- n is an integer from 1 to 6;
- or a pharmaceutically-acceptable salt thereof or stereoisomer thereof.
- In a specific embodiment of interest, the glycopeptide antibacterial agent is a compound of formula I, where: X1 and X2 are both chloro; R1 is —CH2CH2—NH—(CH2)9CH3; R2 is hydroxy; R3 is hydrogen; R4 is methyl; R5 is hydrogen; R6 is hydrogen; and R7 is —CH2—NH—CH2—P(O)(OH)2. This compound is known in the art as telavancin.
- In another specific embodiment of interest, the glycopeptide antibacterial agent is a compound of formula I, where: X1 and X2 are both chloro; R1 is a group of the formula:
- R2 is hydrogen; R3 is hydroxy; R4 is methyl; R5 is hydrogen; R6 is a group of formula (f); and R7 is hydrogen. This compound is known in the art as oritavancin.
- In another specific embodiment of interest, the glycopeptide antibacterial agent is a compound of formula I, where: X1 and X2 are both chloro; R1 is a group of the formula:
- R2 is hydroxy; R3 is H; R4 is methyl; R5 is hydrogen; R6 is hydrogen; and R7 is hydrogen.
- In yet another specific embodiment of interest, the glycopeptide antibacterial agent is dalbavancin.
- In yet another specific embodiment of interest, the glycopeptide antibacterial agent is a teicoplanin. As used herein, the term teicoplanin include teicoplanin A2-1 to 5, i.e., includes one or more of teicoplanin A2-1; teicoplanin A2-2; teicoplanin A2-3; teicoplanin A2-4; and teicoplanin A2-5.
- In a particular embodiment, the glycopeptide antibacterial agent is selected from telavancin, oritavancin, dalbavancin and teicoplanin; or a pharmaceutically acceptable salt thereof.
- Also of interest are derivatives of such compounds, e.g., compounds in which modifications to one or more of the above moieties or groups have been made and which derivatives retain antibacterial activity.
- Such glycopeptide antibacterial agents are commercially available or can be conventionally prepared by techniques known to one of skill in the art. For example, representative patents describing various glycopeptide compounds and derivatives thereof, as well as the synthesis or preparation thereof, include U.S. Pat. Nos. 4,497,802; 4,639,433; 4,643,987; 4,698,327; 5,591,714; 5,750,509; 5,916,873; 5,919,756; 5,840,684; 5,840,684; 5,843,889; 5,977,062; and 6,444,786; as well as published U.S. Application Publication Nos. 2002/0022590 A1; 2003/008812 A1; 2003/0045457 A1; and 200310069391 A1.
- The present invention provides methods of administering a polyene macrolide antifungal agent to a subject in need of treatment. A feature of the present methods is that the polyene macrolide antifungal agent is administered to the subject in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
- By “in combination with” is meant that an amount of a polyene macrolide antifungal agent is administered to the subject together with an amount of a glycopeptide antibacterial agent. In certain embodiments, the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered sequentially, e.g., where the polyene macrolide antifungal agent is administered before or after the glycopeptide antibacterial agent. In other embodiments, the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered simultaneously, e.g., where the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered at the same time as two separate formulations or are combined into a single composition that is administered to the subject. Regardless of whether the polyene macrolide antifungal agent and glycopeptide antibacterial agent are administered sequentially or simultaneously, the agents are considered to be administered together or in combination for purposes of the present invention.
- Routes of administration of the two agents and the amount of each agent employed will depend on various factors, such as the particular agents being used, the condition being treated and so forth. Generally, the amount of the polyene macrolide antifungal agent that is administered to the subject is a therapeutically effective amount to treat the subject for the condition afflicting the subject, e.g., for the fungal infection afflicting the subject. In many embodiments, this effective amount is one that is less than the amount which is effective when the polyene macrolide antifungal agent is not administered in combination with a glycopeptide antibacterial agent (i.e., in a control administration). For example, when administered according to this Invention, the amount of polyene macrolide antifungal agent can typically be reduced by at least about 10% by weight per dose; in other cases, by at least about 20% by weight per dose; and in still other cases, by at least about 50% by weight per dose. In certain representative embodiments, such as when administered by IV infusion, the amount of polyene macrolide antifungal agent that Is administered to the subject ranges from about 0.1 mg/kg to about 25 mg/kg, such as from about 0.25 mg/kg to about 10 mg/kg, including from about 0.5 mg/kg to about 5 mg/kg.
- The amount of glycopeptide antibacterial agent that is administered to the subject is one that typically increases the efficacy of the polyene macrolide antifungal agent, where efficacy is considered to be increased if the amount of the polyene macrolide antifungal agent required to be effective is decreased by at least about 10% by weight per dose. In certain embodiments, the amount of glycopeptide agent administered to the subject is one that results in a synergistic increase in the efficacy of the polyene macrolide antifungal agent. By synergistic increase is meant that the amount of glycopeptide antibacterial agent administered to the subject causes the efficacy of the co-administered polyene macrolide antifungal agent to increase synergistically. Synergy can be demonstrated in vitro using, for example, the checkerboard MIC assay, as described in Eliopoulos, E. G. and R. Moellering, Jr. “Antimicrobial Combinations” in Antibiotics In Laboratory Medicine, edited by V. Lorian, 4th Ed., Williams & Wilkins, Baltimore, Md., pp. 330-396 (1996); Shalit et al., Antimicrobial Agents and Chemotherapy 47(4):1416-1418 (2003); or Afeltra et al., Antimicrobial Agents and Chemotherapy 46(10):3323-3326 (2002); and as illustrated in the Experimental Section herein. In many embodiments, the amount of glycopeptide antibacterial agent that is administered is sufficient to result in a Functional Inhibitory Concentration Index (FICI) of ≦0.7, including ≦0.6, such as ≦0.5, as determined using the MIC assay.
- In certain embodiments, for example, when administered by IV infusion, the amount of glycopeptide antibacterial agent that is administered to the subject in any given dose ranges from about 0.1 mg/kg to about 50 mg/kg, such as from about 0.25 mg/kg to about 25 mg/kg, including from about 0.5 mg/kg to about 10 mg/kg.
- In practicing the methods of this invention, the combination of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent can be administered in a single daily dose or in multiple doses per day. The treatment regimen may require administration over extended periods of time, for example, for several days or for from one to six weeks.
- The polyene macrolide antifungal agent and the glycopeptide antibacterial agent employed in this invention are typically formulated as a pharmaceutical composition suitable for administration to a subject in need of treatment. In this regard, the polyene macrolide antifungal agent and the glycopeptide antibacterial agent may be formulated as separate pharmaceutical compositions for administration simultaneously or sequentially to a subject in need of treatment. Alternatively, such agents may be combined in a single pharmaceutical composition, i.e., one composition that includes both active agents.
- Generally, when formulated and administered as separate pharmaceutical compositions, the polyene macrolide antifungal agent and the glycopeptide antibacterial agent will be formulated using conventional pharmaceutical compositions well known and previous described In the art for such agents. For example, pharmaceutical compositions suitable for polyene macrolide antifungal agents are described in U.S. Pat. Nos. 4,822,777; 4,973,465; 5,077,057; 5,194,266; 5,567,685; 5,616,334; 5,965,158; and 6,413,537. Suitable amphotericin B formulations include, for example, Abelcet®, Amphotec®, Ambisome®, and Fungizone. Additionally, pharmaceutical compositions suitable for glycopeptide antibacterial agents are described in U.S. Pat. Nos. 5,977,062 and 6,635,618; EP 0 667 353; EP 0 525 499; and WO01/82971.
- When the polyene macrolide antifungal agent and the glycopeptide antibacterial agent are formulated together in a single pharmaceutical composition, such compositions are novel. Accordingly, in one embodiment, this invention is directed to a pharmaceutical composition comprising a polyene macrolide antifungal agent; a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms; and a pharmaceutically acceptable carrier, excipient or vehicle.
- By way of further illustration, the polyene macrolide antifungal agent and/or the glycopeptide antibacterial agent can be admixed with conventional pharmaceutical carriers and excipients (i.e., vehicles) and used in the form of aqueous solutions, tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. Such pharmaceutical compositions generally contain, in certain embodiments, from about 0.1 to about 90% by weight of the active compound, and more generally from about 1 to about 30% by weight of the active compound. The pharmaceutical compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, dextrose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid. Disintegrators commonly used in the formulations of this Invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
- A liquid composition will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example, ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting agent, flavoring or coloring agent. Alternatively, a liquid formulation can be prepared from a reconstitutable powder.
- For example, a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstituted with water to form a suspension; and a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.
- A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid compositions. Examples of such carriers include magnesium stearate, starch, lactose, sucrose, microcrystalline cellulose and binders, for example, polyvinylpyrrolidone. The tablet can also be provided with a color film coating, or color included as part of the carrier(s). In addition, active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.
- A composition in the form of a capsule can be prepared using routine encapsulation procedures, for example, by incorporation of active compound and excipients into a hard gelatin capsule. Alternatively, a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example, liquid paraffin or fractionated coconut oil can be prepared and filled into a soft gelatin capsule.
- Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose. Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
- Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.
- The compounds of the invention and their pharmaceutically acceptable salts that are active when given parenterally can be formulated for intramuscular, intrathecal, or intravenous administration.
- A typical composition for intramuscular or intrathecal administration will be of a suspension or solution of active ingredient in an oil, for example, arachis oil or sesame oil. A typical composition for intravenous or intrathecal administration will be a sterile isotonic aqueous solution containing, for example, active ingredient and dextrose or sodium chloride, or a mixture of dextrose and sodium chloride. Other examples are lactated Ringer's injection, lactated Ringers plus dextrose injection, Normosol-M and dextrose, Isolyte E, acylated Ringer's injection, and the like. Optionally, a co-solvent, for example, polyethylene glycol, a chelating agent, for example, ethylenediamine tetraacetic acid, and an anti-oxidant, for example, sodium metabisulphite may be included in the formulation. Alternatively, the solution can be freeze dried and then reconstituted with a suitable solvent just prior to administration.
- The compounds of the invention and their pharmaceutically acceptable salts which are active on rectal administration can be formulated as suppositories. A typical suppository formulation will generally consist of active ingredient with a binding and/or lubricating agent such as a gelatin or cocoa butter or other low melting vegetable or synthetic wax or fat.
- The compounds of this invention and their pharmaceutically acceptable salts which are active on topical administration can be formulated as transdermal compositions or transdermal delivery devices (“patches”). Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive. Such transdermal patches may be used to provide continuous or discontinuous Infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, for example, U.S. Pat. No. 5,023,252, issued Jun. 11, 1991. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- In certain embodiments, the pharmaceutical composition containing the glycopeptide antibacterial agent will further comprise a cyclodextrin compound. By way of illustration, the glycopeptide antibacterial agent, for example, in the form a pharmaceutically acceptable salt, can be admixed with an aqueous cyclodextrin solution to form a pharmaceutical composition. Such pharmaceutical compositions will typically contain from about 1 to about 40 weight percent of the cyclodextrin and an effective amount of the glycopeptide antibacterial agent. In certain embodiments, the cyclodextrin employed in the pharmaceutical compositions of this invention is hydroxypropyl-β-cyclodextrin or sulfobutyl ether β-cyclodextrin. In certain embodiments, the cyclodextrin is hydroxypropyl-β-cyclodextrin. In certain embodiments, the cyclodextrin will comprise about 1 to 40 weight percent; such as about 2 to 30 weight percent; including about 5 to 15 weight percent, of the formulation. In an embodiment, the aqueous cyclodextrin solution further comprises dextrose, e.g., about 5% dextrose.
- Optionally, the pharmaceutical composition may contain other pharmaceutically acceptable components, such a buffers, surfactants, antioxidants, viscosity modifying agents, preservatives and the like. Each of these components is well known in the art. See, for example, U.S. Pat. No. 5,985,310.
- Other components suitable for use in the formulations of the present invention can be found in Remington. The Science and Practice of Pharmacy, 20th Edition, Lippinott Williams & White, Baltimore, Md. (2000).
- This invention also provides kits and systems for use in practicing the methods described herein. For example, kits and systems for practicing the such methods may include one or more pharmaceutical formulations, which include one or both of the polyene macrolide antifungal agent and the glycopeptide antibacterial agent. For example, in certain embodiments, the kits may include a single pharmaceutical composition, present as one or more unit dosages, where the composition comprises both the polyene macrolide antifungal agent and the glycopeptide antibacterial agent. In yet other embodiments, the kits may include two or more separate pharmaceutical compositions, each containing either a polyene macrolide antifungal agent or a glycopeptide antibacterial agent.
- In addition to the above components, the kits may further include instructions for practicing the methods of this invention. These instructions may be present in the kits in a variety of forms, one or more of which may be present in the kit. One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc. Yet another means would be a computer readable medium, e.g., diskette, CD, etc., on which the information has been recorded. Yet another means that may be present is a website address which may be used via the internet to access the information at a removed site. Any convenient means for providing instructions may be present in the kits.
- The term “system” as used herein means a collection of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent, present in a single or disparate composition, that are brought together for the purpose of practicing the methods of this invention. For example, separately obtained polyene macrolide antifungal agent and glycopeptide antibacterial agent dosage forms brought together and co-administered to a subject in need of treatment, according to the present invention, are a system according to the present invention.
- The methods, compositions, kits and systems of this invention are useful for treating a subject having a fungal infection or medical condition which is caused by a pathogenic organism, e.g., a fungus, that is inhibited by or treatable with a polyene macrolide antifungal agent. In this regard, the subject may already have a fungal Infection or the combination of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent may be used in prophylactic therapy and empirical therapy where treatment is initiated prior to the identification of the causative pathogen.
- A variety of subjects or patients or hosts are treatable using the methods, compositions, kits and systems of the present invention. Generally such subjects are “mammals” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In a particular embodiment of Interest, the subject or patient is a human.
- Representative fungal infections or medical conditions that may be treated include those caused by the following pathogenic species: Candida spp., such as C. albicans, C. krusei, C. glabrata, C. tropicalis, C. parapsilosis, C. guilliermorulii, C. haemulonii, C. iusitaniae, C. neoformans, C. norvegensis, C. viswanathii, and C. kefyr; Hyaline molds, such as Aspergillus fumigatus, A. flavus, A. niger, F. moniliforme, Geotricium candidum; Histoplasma capsulatum (var. capsulatum), Coccidioides immitis, Cryptococcus neoformans (var. neoformans, and var. gattii), C. bidus, C. laurentii, and C. fusarium, as well as Mucormycotic organisms, e.g., Zygomycetes spp.; such as Rhizopus oryzae, R. micropsorus, R. pusillus, Cunninghamelle bertholletiae, Saksenaea vasiformis, Mucor circinelloides, M. ramosissimus, Absidia corymbifera, Apophysomyces elegans, Cokeromyces recurvatus, and Syncephalastrum racemosum.
- Accordingly, the present invention provides a method of treating a fungal infection in a subject, the method comprising administering to the subject an antifungal amount, e.g., an amount effective to treat the subject, of a polyene macrolide antifungal agent and a glycopeptide antibacterial agent as further described herein.
- The compositions of this invention may also be used for coating of medical instruments or implants, agricultural applications, etc. as described further, for example, in U.S. Pat. No. 6,541,506.
- In certain embodiments, the subject being treated suffers from both a fungal infection and a bacterial infection, where the bacterial infection is responsive to the glycopeptide antibacterial agent employed in this invention. Accordingly, this invention also provides a method for treating a bacterial infection and a fungal infection in a subject in need of treatment, the method comprising administering to the subject an antifungal amount of a polyene macrolide antifungal agent and an antibacterial amount of a glycopeptide antibacterial agent as further described herein.
- Representative bacterial infections or medical conditions that may be treated include those caused by the following staphylococci, including methicillin-resistant staphylococci; enterococci, including vancomycin-resistant enterococci (VRE); severe staphylococcal infections, such as staphylococcal endocarditis and staphylococcal septicemia; and the like.
- The utility of present invention is further illustrated by the following representative Examples.
- The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this Invention. In the examples below, the following abbreviations have the following meanings unless otherwise indicated. All other abbreviations have their generally accepted meaning.
- CFU/mL colony-forming units/milliliter
DMSO Dimethyl sulfoxide
FIC fractional inhibitory concentration
FICI fractional inhibitory concentration index - MIC minimum inhibitory concentration
MOPS (3-[N-Morpholino]propanesulfonic acid)
OD optical density - The following assay was used to determine the minimum inhibitory concentration (MIC) and fractional inhibitory concentration index (FICI) for combinations of an antifungal agent and a glycopeptide antibacterial agent. This assay and methods for calculating FICI are well known in the art. See, for example, Eliopoulos, E. G. and R. Moellering, Jr. “Antimicrobial Combinations” in Antibiotics in Laboratory Medicine, edited by V. Lorian, 4th Ed., Williams & Wilkins, Baltimore, Md., pp. 330-396 (1996); Shalit et al., Antimicrobial Agents and Chemotherapy 47(4):1416-1418 (2003); or Afeltra et al., Antimicrobial Agents and Chemotherapy 46(10):3323-3326 (2002).
- FICI values are typically classified as followings:
- FICI=0.5 Synergistic effect
- 0.5<FICI<1.0 Additive effect
- 1.0<FICI<4.0 Indifferent effect
- FICI>4.0 Antagonistic effect
- In this assay, a combination of an antifungal agent and a glycopeptide antibacterial agent was considered to be more effective than the antifungal agent alone, if the combined compounds demonstrated either a calculated FICI of less than or equal to about 0.5 or a decrease of the antifungal MIC by at least a one-fold dilution factor.
- The fungal strains used in this assay are highly infectious. Standard safety measures, such as use of disposable screw cap tubes and use of safety masks, were strictly followed. All work was conducted in a Biosafety Level 2 cabinet. All materials and equipment (e.g., pipettors and Incubators) were decontaminated between experiments.
- The fungal strains used in this assay were obtained from the American Type Culture Collection (ATCC), Manassas, Va. In the table below, the ATCC deposit number for each strain is indicated under the column heading “ATCC”. Other strains can be used if desired.
-
-
Strains ATCC Source/Description Candida albicans 24433 Nail infection Candida albicans 90028 Blood, Iowa Candida parapsilosis 22019 Case of spruce, Puerto Rico Candida parapsilosis 90018 Blood, Virginia Candida tropicalis 750 Patient with bronchomycosis Candida krusei 32672 Human, New Zealand Candida glabrata 200918 Human tongue, Santa Rosa, California Cryptococcus neoformans 14117 Human meningitis Cryptococcus neoformans 56991 Human, Zaire -
-
Strains ATCC Source/Description Aspergillus fumigatus 14110 Human sputum Aspergillus flavus 64025 Human sputum, Ohio Fusarium moniliforme 38159 Human, California Geotricium candidum 62231 Ulcer in human mouth Pseudallescheria boydii 36283 Human brain abcess -
-
Strains ATCC Source/Description Mucor circinelloides 26759 Tom wounds, human, Canada Rhizopus microsporus 14050 Fatal human Rhizopus infection - Procedures, protocols, supplies and equipment used in this assay follow the recommendations approved and published by the National Committee for Clinical Laboratory Standards (NCCLS), Wayne, Pa. as described in NCCLS 2003, “Reference Method for Broth Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard” (NCCLS document M7-A6); NCCLS 2002, “Reference Method for Broth Dilution Antifungal Susceptibility Tests of Filamentous Fungi that Grow Aerobically; Approved Standard” (NCCLS document M38-A); and NCCLS 2002 “Reference Method for Broth Dilution Antifungal Susceptibility Tests of Yeast; Approved Standards-2nd Edition” (NCCLS document M27-A2).
- The following semi-synthetic glycopeptide antibacterial agents were tested in this assay:
- wherein R1 and R7 are as defined as follows:
- Compounds 1 and 2 were prepared as described in Example 2 of U.S. Provisional Appl. No. 2002/0022590 A1, published on Feb. 21, 2002. Compound 3 was prepared from vancomycin and 4-(4′-chlorophenyl)benzaldehyde using the procedures described in U.S. Pat. No. 6,392,012, issued on May 21, 2002.
- Vancomycin was purchased from Sigma-Aldrich (St. Louis, Mo.). Telcoplanin was purchased from a pharmacy in Germany as i.v. infusion Targocid®.
- Amphotericin B and miconazole were purchased from U.S. Pharmacopeia (Rockville, Md.). Fluconazole and voriconazole (formulated as Vfend®) were purchased from Peninsula Pharmacy (Burlingame, Calif.). Fluconazole was purchased as Diflucan® (oral formulation) and purified prior to use.
- An initial stock of each compound was made in an appropriate solvent, i.e., either a DMSO solution for Compounds 1, 2 and 3, amphotericin B, vancomycin and fluconazole; or a sterile water solution according to the instruction of the supplier for voriconazole and teicoplanin.
- Using a checkerboard method, a 2-fold dilution 100× final concentration master plate was prepared using a 96-well U-shape microtiter plate and an appropriate solvent. In the “checkerboard” method, a microtiter plate is divided into “columns” in which each well in the column contains the same amount of an antifungal agent (Compound A) being diluted along the x-axis, and “rows” in which each well in the row contains the same amount of a glycopeptide antibacterial agent (Compound B) being diluted on the y-axis. Also included is a row (or column) for Compound A or B alone. The dilutions used in the checkerboard are exponential (by powers of two). The result is that each well in the microtiter plate contains a unique concentration of the two compounds being tested.
- A matrix 2× final concentration was performed by transferring 30 μL of 100× Compound A and Compound B into a 1,440 μL RPMI in deep wells (one deep well per drug combination). After mixing, 100 μL of 2× drug combinations were distributed into 96-well microtiter plates. Compound A was diluted from Column 1 starting at 1,600 μg/mL to Column 11 (1.6 μg/mL). Wells in Column 1 contained a final concentration (after inoculum was added) of 16 μg/mL of Compound A; wells in Column 2 contained a final concentration of 8 μg/mL of Compound A; wells in Column 3 contained a final concentration of 4 μg/mL of Compound A; etc. Compound A was not added to Column 12, so Column 12 contained only Compound B.
- Compound B was diluted from row A starting at 6,400 μg/mL down to row G (100 μg/mL). Wells in Row A contained a final concentration of 64 μg/mL of Compound B; Row B contained a final concentration of 32 μg/mL of Compound B; Row C contained a final concentration of 16 μg/mL of Compound B; etc. Compound B was not added to Row H, so Row H only contained Compound A.
- Shown below is an example of a 96-well microtiter plate format used with combined Compound A and Compound B. Concentrations noted on the rows and columns are the final ones after inoculum were mixed with the combined compounds.
-
Compound Compound A (μg/mL final) Compound B 16 8 4 2 1 0.5 0.25 0.125 0.063 0.031 0.015 0 B (μg/mL final) 1 2 3 4 5 6 7 8 9 10 11 12 (μg/mL final) 64 A A 64 32 B B 32 16 C C 16 8 D D 8 4 E E 4 2 F F 2 1 G G 1 0 H H 0 1 2 3 4 5 6 7 8 9 10 11 12 16 8 4 2 1 0.5 0.25 0.125 0.063 0.031 0.015 0 - In most cases, the MIC of the glycopeptide antibacterial agent alone was >64 μg/mL. In order to get an accurate measurement, a standard MIC assay using NCCLS protocols was performed with an extended concentration range of from 256 μg/mL to 0.25 μg/mL. The MIC of the glycopeptide antibacterial agent determined from this experiment was used in FIC calculations. If the MIC of the glycopeptide antibacterial agent was >256 μg/mL, FIC of the compound was calculated using 256 μg/mL as the closest value to the true MIC.
- RPMI-1640 without sodium bicarbonate media (GIBCO-BRL, Carlsbad, Calif.), an enriched media formulated for mammalian cells, was used according to the NCCLS guidelines for yeast and filamentous fungi susceptibility testing. The medium was buffered with 0.165 M 3-[N-Morpholino]propanesulfonic acid (MOPS) supplemented with 20 g/L glucose and pH adjusted to 7.0 with hydrogen chloride. Sabouraud Dextrose Agar (SDA) slants and plates, and Potato Dextrose Agar (PDA) plates were purchased from Hardy Diagnostic (Santa Maria, Calif.).
- Yeast cultures were started from −80° C. frozen stock streaked on SDA slants and incubated at 35° C. under aerobic conditions for 24 h. The slants were kept in the refrigerator for up to 2 weeks and used regularly as a starting culture. About 24 to 48 h before each assay was run, yeasts were streaked on SDA plates for isolated colonies. To prepare the inoculum, from one to four colonies were resuspended in 5 mL of saline, and vortexed for 15 sec.
- Molds started from −80° C. frozen stocks were spotted in the center of the PDA plates. The plates were incubated at 35° C. for 7 days to induce conidiospores and sporangiospores. Fast growing molds (i.e., Fusarium spp. and Rhizopus spp.) were incubated at 35° C. for 48 to 72 h, then kept at 25-28° C. for up to 7 days. To prepare the inoculum, the mold spores were resuspended in saline (avoiding aerosol formation), then vortexed for 15 sec, and the hypheal particles were allowed to settle for 5 to 10 min.
- The initial optical density (OD) at 530 nm of the vortexed cells suspended in saline was less than 0.5 as measured using a SmartSpec 3000 spectrophotometer (BioRAD, Hercules, Calif.). For most yeast and mold cultures, the optical density (OD) of the suspension was adjusted to 0.11 in saline to provide ˜0.4×106 CFU/mL. However, for Fusarium moniliforme and Pseudallescheria boydii the OD of the suspension was adjusted to OD=0.17 to provide ˜0.4×106 CFU/mL. Then the culture was diluted 1:1,000 for yeasts and 1:50 for molds in RPMI media (GIBCO-BRL) to get a 2× final inoculum. A final inoculum of 0.5×103 to 2.5×103 CFU/mL (yeasts) and 0.4×104 to 5×104 CFU/mL (molds) was used to ensure greater reproducibility of test results.
- Using an 8-channel multipipetter, 100 μL of the 2× inoculum was added to 100 μL of 2× drug dilution starting from the lowest dilution to the highest. Microtiter plates were incubated at 35° C. under aerobic conditions for 48 h before reading the results. Plates were read after about 24 h (Rhizopus spp.) or 72 h (Cryptococcus neoformans).
- Additionally, for validation purposes (i.e., to confirm the accuracy of the pipetted inoculum amount and the viability of cells) 100 μL of the inoculum was plated on a separate SDA plate. If, after about 46 to about 48 hours, the inoculum size calculated from the colony count on the validation plate was outside the expected range of 0.5×103 to 2.5×103 CFU/mL (yeasts) and 0.4×104 to 5×104 CFU/mL (molds), the entire assay test was redone.
- After about 46 to about 48 hours, the growth of the fungus in the 96-well microtiter plates was evaluated and the minimum inhibitory concentration (MIC) and fractional inhibitory concentration (FIC) were calculated.
- Each column and row of the microtiter plates was visually assessed for cell growth, which manifested as clouding or turbidity of the media. RPMI media was clear and transparent at Inoculation. When no turbidity was observed, the growth of the inoculum cells was inhibited, and the well remained clear.
- The minimum inhibitory concentration (MIC) of a compound, i.e., the minimum inhibitory concentration of compound A (MICA), is the concentration of compound A at which no growth is observed.
- To measure the in vitro interactions of test compounds, the Fractional Inhibitory Concentration was calculated using the concentration that reduced the antifungal compound MIC by at least a 2-fold dilution factor (i.e., “concentration of compound in synergistic well”). The Fractional Inhibitory Concentration for compound A, FIC(A), is equal to the concentration of compound A in synergistic well divided by MIC(A). Similarly, for compound B, the FIC(B) is equal to the concentration of compound B in synergistic well divided by MIC(B). The Fractional Inhibitory Concentration Index (FICI) is equal to the sum of FIC(A)+FIC(B).
-
- For each combination of test compounds, the assay was repeated at least twice to show reproducibility. Because MICs have an inherent 50% error associated with the assay, no average or statistical analysis was performed. FICs however are not affected by the MIC variability.
- The calculated value for the FICI of the combined test compounds was compared to the following standards in certain embodiments:
- FICI=0.5 synergistic effect
- FICI>0.5 nonsynergistic effect
- The interactions of the combined compounds can be expressed as a graph in which antifungal MIC (μg/mL) is plotted on the Y-axis as a function of antibacterial concentration (μg/mL) which is plotted on X-axis. If desired, the synergistic interaction of the two combined compounds can alternatively be calculated or validated with other assays, such as a time-kill synergy assay as discussed in Eliopoulos, E. G. and R. Moellering, Jr.
- The results of the assays are shown in Tables 1, 2 and 3.
-
TABLE 1 FICI for Combinations of Glycopeptide Antibacterial Agents and Amphotericin B FICI Cmpd. Cmpd. Cmpd. Teico- Vanco- Fungal Strain 1 2 3 planin mycin C. albicans 24433 0.31 0.28 0.31 0.53 2.00 C. parapsilosis 22019 0.31 0.31 0.28 0.38 2.00 C. tropicalis 750 0.31 0.28 0.31 0.38 2.00 C. krusei 32672 0.31 0.31 0.28 0.38 2.00 -
TABLE 2 FICI for Combinations of Compound 1 and Amphotericin B or Nystatin FICI Fungal Strain Amphotericin B Nystatin C. albicans ATCC 24433 0.19 0.31 C. parapsilosis ATCC 22019 0.28 0.31 C. tropicalis ATCC 750 0.27 0.31 C. krusei ATCC 32672 0.31 0.50 C. glabrata ATCC 200918 0.19 0.31 C. neoformans ATCC 56991 0.25 0.5 A. fumigatus ATCC 14110 0.31 1.25 A. flavus ATCC 64025 0.51 0.51 F. moniliforme ATCC 38159 0.53 0.51 G. candidum ATCC 62231 0.63 0.31 M. circinelloides ATCC 26759 0.26 0.28 R. miscrosporus ATCC 14050 0.27 0.51 P. boydii ATCC 38283 0.38 0.38 -
TABLE 3 FICI for Combinations of Compound 1 and Azole Antifungal Agents FICI Flucon- Micon- Voricon- Fungal Strain azole azole azole C. albicans ATCC 24433 2.00 2.00 Not Applicable C. parapsilosis ATCC 2.00 2.00 Not 22019 Applicable C. tropicalis ATCC 750 2.00 2.00 Not Applicable C. krusei ATCC 32672 2.00 Not 1.13 Determined C. glabrata ATCC 200918 2.00 Not 1.13 Determined - The data in Tables 1, 2 and 3 demonstrate that combinations of a polyene macrolide antifungal agent, such as amphotericin B or nystatin, and a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms typically have a synergistic or additive effect against various strains of fungi.
- In contrast, the combination of vancomycin and amphotericin B was not synergistic or additive. Moreover, azole antifungal agents did not show a synergistic or additive effect when combined with the glycopeptide antibacterial agents.
- These results clearly demonstrate that the present invention provides significant advantages for administering a polyene macrolide antifungal agent to a subject in need thereof. More specifically, by administering such a polyene macrolide antifungal agent in combination with a specified glycopeptide antibacterial agent, the efficacy of the polyene macrolide antifungal agent is significantly increased thereby allowing for reduced dosages (e.g., to reduce or eliminate toxicity), quicker treatment protocols, etc.
- While the present invention has been described with reference to specific aspects or embodiments thereof, it will be understood by those of ordinary skill in the art that various changes can be made or equivalents can be substituted without departing from the true spirit and scope of the invention. Additionally, to the extent permitted by applicable patent statues and regulations, all publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety to the same extent as if each document had been individually incorporated by reference herein.
Claims (22)
1-26. (canceled)
27. A pharmaceutical composition comprising:
(a) a polyene macrolide antifungal agent;
(b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms; and
(c) a pharmaceutically acceptable carrier.
28. The pharmaceutical composition according to claim 27 , wherein the polyene macrolide antifungal agent is amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin, candicidin or pimaricin; or a pharmaceutically acceptable salt thereof.
29. The pharmaceutical composition according to claim 27 , wherein the glycopeptide antibacterial agent is selected from telavancin, oritavancin, dalbavancin and teicoplanin; or a pharmaceutically acceptable salt thereof.
30. The pharmaceutical composition according to claim 27 , wherein the glycopeptide antibacterial agent is a compound of formula I:
wherein
X1 and X2 are independently hydrogen or chloro;
R1 is selected from the group consisting of:
(a) —Ra;
(b) —C(O)—Rb;
(c) —Rc—W1;
(d) —C(O)—Rd—W2; and
(e) —Re—Y—Rf;
where
Ra and Rb are independently C8-14 alkyl, C8-14 alkenyl or C8-14 alkynyl;
Rc and Rd are independently C1-8 alkylene;
Re is C2-8 alkylene;
Rf is C1-12 alkyl, C2-12 alkenyl or C2-12 alkynyl;
W1 and W2 are independently phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, -(phenyl), —CH2— (phenyl), —O-(phenyl), and
—O—CH2— (phenyl); wherein each -(phenyl) group is optionally substituted with 1 or 2 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy and halo;
Y is O, S or NH;
and provided that R1 comprises at least 8 carbon atoms;
one of R2 and R3 is hydroxy and the other is hydrogen;
R4 and R5 are independently hydrogen or methyl;
R6 is hydrogen or a group of formula (f):
R7 is hydrogen or a group of formula (g):
n is an integer from 1 to 6;
or a pharmaceutically-acceptable salt thereof or stereoisomer thereof.
31. The pharmaceutical composition according to claim 30 , wherein:
X1 and X2 are both chloro;
R1 is —CH2CH2—NH—(CH2)9CH3;
R2 is hydroxy;
R3 is hydrogen;
R4 is methyl;
R5 is hydrogen;
R6 is hydrogen; and
R7 is —CH2—NH—CH2—P(O)(OH)2.
32. The pharmaceutical composition according to any one of claims 29 , 30 and 31 , wherein the polyene macrolide antifungal agent is amphotericin B.
33. A kit comprising:
(a) a polyene macrolide antifungal agent; and
(b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
34. The kit according to claim 33 , wherein the kit further comprises instructions for administering the polyene macrolide antifungal agent and the glycopeptide antibacterial agent to a subject.
35. The kit according to claim 33 , wherein the polyene macrolide antifungal agent and the glycopeptide antibacterial agent are present as separate pharmaceutical compositions.
36. The kit according to claim 33 , wherein the polyene macrolide antifungal agent and the glycopeptide antibacterial agent are present in a single pharmaceutical composition.
37. The kit according to claim 33 , wherein the polyene macrolide antifungal agent is amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin, candicidin or pimaricin; or a pharmaceutically acceptable salt thereof.
38. The kit according to claim 33 , wherein the glycopeptide antibacterial agent is selected from telavancin, oritavancin, dalbavancin and teicoplanin; or a pharmaceutically acceptable salt thereof.
39. The kit according to claim 33 , wherein the glycopeptide antibacterial agent is a compound of formula I:
wherein
X1 and X2 are independently hydrogen or chloro;
R1 is selected from the group consisting of:
(a) —Ra;
(b) —C(O)—Rb;
(c) —Rc—W1;
(d) —C(O)—Rd—W2; and
(e) —Re—Y—Rf;
where
Ra and Rb are independently C8-14 alkyl, C8-14 alkenyl or C8-14 alkynyl;
Rc and Rd are independently C1-8 alkylene;
Re is C2-8 alkylene;
Rf is C1-12 alkyl, C2-12 alkenyl or C2-12 alkynyl;
W1 and W2 are independently phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, -(phenyl), —CH2— (phenyl), —O-(phenyl), and
—O—CH2— (phenyl); wherein each -(phenyl) group is optionally substituted with 1 or 2 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy and halo;
Y is O, S or NH;
and provided that R1 comprises at least 8 carbon atoms;
one of R2 and R3 is hydroxy and the other is hydrogen;
R4 and R5 are independently hydrogen or methyl;
R6 is hydrogen or a group of formula (f):
R7 is hydrogen or a group of formula (g):
n is an integer from 1 to 6;
or a pharmaceutically-acceptable salt thereof or stereoisomer thereof.
40. The kit according to claim 39 , wherein:
X1 and X2 are both chloro;
R1 is —CH2CH2—NH—(CH2)9CH3;
R2 is hydroxy;
R3 is hydrogen;
R4 is methyl;
R5 is hydrogen;
R6 is hydrogen; and
R7 is —CH2—NH—CH2—P(O)(OH)2.
41. The kit according to any one of claims 38 , 39 and 40 , wherein the polyene macrolide antifungal agent is amphotericin B.
42. A system for treating a fungal infection in a subject, the system comprising:
(a) a polyene macrolide antifungal agent; and
(b) a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms.
43. The system according to claim 42 , wherein the polyene macrolide antifungal agent is amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin, candicidin or pimaricin; or a pharmaceutically acceptable salt thereof.
44. The system according to claim 42 , wherein the glycopeptide antibacterial agent is selected from telavancin, oritavancin, dalbavancin and teicoplanin; or a pharmaceutically acceptable salt thereof.
45. The system according to claim 42 , wherein the glycopeptide antibacterial agent is a compound of formula I:
wherein
X1 and X2 are independently hydrogen or chloro;
R1 is selected from the group consisting of:
(a) —Ra;
(b) —C(O)—Rb;
(c) —Rc—W1;
(d) —C(O)—Rd—W2; and
(e) —Re—Y—Rf;
where
Ra and Rb are independently C8-14 alkyl, C8-14 alkenyl or C8-14 alkynyl;
Rc and Rd are independently C1-8 alkylene;
Re is C2-8 alkylene;
Rf is C1-12 alkyl, C2-12 alkenyl or C2-12 alkynyl;
W1 and W2 are independently phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, -(phenyl), —CH2— (phenyl), —O-(phenyl), and
—O—CH2— (phenyl); wherein each -(phenyl) group is optionally substituted with 1 or 2 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy and halo;
Y is O, S or NH;
and provided that R1 comprises at least 8 carbon atoms;
one of R2 and R3 is hydroxy and the other is hydrogen;
R4 and R5 are independently hydrogen or methyl;
R6 is hydrogen or a group of formula (f):
R7 is hydrogen or a group of formula (g):
n is an integer from 1 to 6;
or a pharmaceutically-acceptable salt thereof or stereoisomer thereof.
46. The system according to claim 45 , wherein:
X1 and X2 are both chloro;
R1 is —CH2CH2—NH—(CH2)9CH3;
R2 is hydroxy;
R3 is hydrogen;
R4 is methyl;
R5 is hydrogen;
R6 is hydrogen; and
R7 is —CH2—NH—CH2—P(O)(OH)2.
47. The system according to any one of claims 44 , 45 and 46 , wherein the polyene macrolide antifungal agent is amphotericin B.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/332,880 US20090215674A1 (en) | 2003-05-27 | 2008-12-11 | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47352303P | 2003-05-27 | 2003-05-27 | |
US10/854,575 US7521418B2 (en) | 2003-05-27 | 2004-05-26 | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
US12/332,880 US20090215674A1 (en) | 2003-05-27 | 2008-12-11 | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/854,575 Division US7521418B2 (en) | 2003-05-27 | 2004-05-26 | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090215674A1 true US20090215674A1 (en) | 2009-08-27 |
Family
ID=33551451
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/854,575 Active 2025-11-06 US7521418B2 (en) | 2003-05-27 | 2004-05-26 | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
US12/332,880 Abandoned US20090215674A1 (en) | 2003-05-27 | 2008-12-11 | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/854,575 Active 2025-11-06 US7521418B2 (en) | 2003-05-27 | 2004-05-26 | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
Country Status (4)
Country | Link |
---|---|
US (2) | US7521418B2 (en) |
EP (1) | EP1641480A1 (en) |
JP (2) | JP2006528704A (en) |
WO (1) | WO2004110473A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006528704A (en) * | 2003-05-27 | 2006-12-21 | セラヴァンス インコーポレーテッド | Use of polyene macrolide antifungal agents in combination with glycopeptide antibacterial agents |
ES2298821T3 (en) | 2003-07-22 | 2008-05-16 | Theravance, Inc. | USE OF AN ANTIFUNGIC EQUINOCANDINE AGENT IN COMBINATION WITH AN ANTIBACTERIAL GLICOPEPTIDIC AGENT. |
US20070185015A1 (en) * | 2005-02-28 | 2007-08-09 | Chiron Corporation and North China Pharmaceutical Corporation | Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity |
US7632918B2 (en) * | 2005-02-28 | 2009-12-15 | Novartis Vaccines And Diagnostics, Inc. | Semi-synthetic glycopeptides with antibiotic activity |
US7368422B2 (en) * | 2005-02-28 | 2008-05-06 | Novartis Vaccines And Diagnostics Inc. | Semi-synthetic rearranged vancomycin/desmethyl-vancomycin-based glycopeptides with antibiotic activity |
EP1911836A1 (en) | 2006-10-12 | 2008-04-16 | AVIR Green Hills Biotechnology Trading GmbH | Medium supplement for virus production |
CA2710602A1 (en) * | 2007-12-26 | 2009-07-09 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
US8933068B2 (en) * | 2008-05-09 | 2015-01-13 | Nbr Pathfinder Llc | Composition and methods of treatment of bacterial meningitis |
WO2010048340A2 (en) * | 2008-10-24 | 2010-04-29 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
GB2465863A (en) * | 2008-12-05 | 2010-06-09 | Lead Therapeutics Inc | Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections |
JP6543272B2 (en) * | 2014-05-16 | 2019-07-10 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois | Amphotericin B derivatives with reduced toxicity |
AR100034A1 (en) * | 2015-01-30 | 2016-09-07 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | A PHARMACEUTICAL COMPOSITION SOLUBLE IN WATER THAT INCLUDES, AT LEAST, A THERAPEUTICALLY ACTIVE SUBSTANCE AND, AT LEAST, A CAPACITY SUBSTANCE TO FORM MICELAS |
US20170239323A1 (en) * | 2016-02-18 | 2017-08-24 | The Medicines Company | Oritavancin formulations |
AU2018273887B2 (en) | 2017-05-22 | 2022-09-08 | Insmed Incorporated | Lipo-glycopeptide cleavable derivatives and uses thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2797183A (en) * | 1952-01-07 | 1957-06-25 | Research Corp | Nystatin and method of producing it |
US2908611A (en) * | 1954-12-28 | 1959-10-13 | Olin Mathieson | Amphotericin b, its production, and its salts |
US5741782A (en) * | 1996-03-29 | 1998-04-21 | Cryolife, Inc. | Antibiotic cocktail and method of use |
US5925616A (en) * | 1996-08-09 | 1999-07-20 | Buckman Laboratories International, Inc. | Treatment of fungal infections using a combination of an anti-fungal compound and an H-alkyl heterocyclic compound |
US20020035096A1 (en) * | 1999-09-14 | 2002-03-21 | Lawter James Ronald | Formulations for treating or preventing mucositis |
US6635618B2 (en) * | 2000-06-22 | 2003-10-21 | Theravance, Inc. | Glycopeptide phosphonate derivatives |
US6719991B2 (en) * | 2000-06-09 | 2004-04-13 | Baylor College Of Medicine | Combination of antimicrobial agents and bacterial interference to coat medical devices |
US7521418B2 (en) * | 2003-05-27 | 2009-04-21 | Theravance, Inc. | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0525499A1 (en) | 1991-07-29 | 1993-02-03 | GRUPPO LEPETIT S.p.A. | Amide derivatives of antibiotic A 40926 |
MY128335A (en) | 1994-01-28 | 2007-01-31 | Lilly Co Eli | Glycopeptide antibiotic derivatives |
AUPQ066399A0 (en) | 1999-05-31 | 1999-06-24 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal combination use |
EP1278549B1 (en) * | 2000-05-02 | 2008-12-10 | Theravance, Inc. | Composition containing a cyclodextrin and a glycopeptide antibiotic |
-
2004
- 2004-05-26 JP JP2006533435A patent/JP2006528704A/en not_active Ceased
- 2004-05-26 EP EP04753471A patent/EP1641480A1/en not_active Withdrawn
- 2004-05-26 WO PCT/US2004/016644 patent/WO2004110473A1/en active Application Filing
- 2004-05-26 US US10/854,575 patent/US7521418B2/en active Active
-
2008
- 2008-12-11 US US12/332,880 patent/US20090215674A1/en not_active Abandoned
-
2010
- 2010-07-27 JP JP2010168705A patent/JP2010241841A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2797183A (en) * | 1952-01-07 | 1957-06-25 | Research Corp | Nystatin and method of producing it |
US2908611A (en) * | 1954-12-28 | 1959-10-13 | Olin Mathieson | Amphotericin b, its production, and its salts |
US5741782A (en) * | 1996-03-29 | 1998-04-21 | Cryolife, Inc. | Antibiotic cocktail and method of use |
US5925616A (en) * | 1996-08-09 | 1999-07-20 | Buckman Laboratories International, Inc. | Treatment of fungal infections using a combination of an anti-fungal compound and an H-alkyl heterocyclic compound |
US20020035096A1 (en) * | 1999-09-14 | 2002-03-21 | Lawter James Ronald | Formulations for treating or preventing mucositis |
US6719991B2 (en) * | 2000-06-09 | 2004-04-13 | Baylor College Of Medicine | Combination of antimicrobial agents and bacterial interference to coat medical devices |
US6635618B2 (en) * | 2000-06-22 | 2003-10-21 | Theravance, Inc. | Glycopeptide phosphonate derivatives |
US7521418B2 (en) * | 2003-05-27 | 2009-04-21 | Theravance, Inc. | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
Also Published As
Publication number | Publication date |
---|---|
US20040242505A1 (en) | 2004-12-02 |
US7521418B2 (en) | 2009-04-21 |
JP2006528704A (en) | 2006-12-21 |
WO2004110473A1 (en) | 2004-12-23 |
JP2010241841A (en) | 2010-10-28 |
EP1641480A1 (en) | 2006-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7902148B2 (en) | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | |
US20090215674A1 (en) | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent | |
US6858584B2 (en) | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin | |
US8541375B2 (en) | Glycopeptide phosphonate derivatives | |
US20030060598A1 (en) | Glycopeptide derivatives and pharmaceutical compositions containing the same | |
EP2278989B1 (en) | Oritavancin for inhibiting and treating biofilms | |
US6828299B2 (en) | Polyhydroxy glycopeptide derivatives | |
US6770621B2 (en) | Polyacid glycopeptide derivatives | |
US6620781B2 (en) | Glycopeptide carboxy-saccharide derivatives | |
KR20140041493A (en) | Vaginal composition based on alkyl polyglucosides | |
CA2538842A1 (en) | A glycopeptide composition with improved antibiotic activity | |
CN109364062B (en) | Antifungal pharmaceutical composition | |
JPWO2007074727A1 (en) | Oral candidiasis treatment | |
US20030078371A1 (en) | Glycopeptide disulfide and thioester derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC, CALIFORN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THERAVANCE, INC.;REEL/FRAME:033200/0041 Effective date: 20140601 |